FISEVIER

Contents lists available at ScienceDirect

EClinicalMedicine



journal homepage: https://www.journals.elsevier.com/eclinicalmedicine

Research Paper

Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action

Lin Liu, MSc^{a,b,1}, Shu-Yu Ni, MSc^{a,b,1}, Wei Yan, PhD^{c,1}, Qing-Dong Lu, MSc^{a,b},

Yi-Miao Zhao, MSc^{a,b}, Ying-Ying Xu, MSc^{a,b}, Huan Mei, MSc^{a,b}, Le Shi, PhD^c, Kai Yuan, PhD^c,

Ying Han^a, Jia-Hui Deng, PhD^c, Yan-Kun Sun, PhD^c, Shi-Qiu Meng, PhD^a,

Zheng-Dong Jiang, MD^d, Na Zeng, MPH^{a,b,e}, Jian-Yu Que, MD^c, Yong-Bo Zheng, MD^c,

Bei-Ni Yang, MSc^{a,b}, Yi-Miao Gong, MSc^c, Arun V. Ravindran, MD^f, Thomas Kosten, MD^g,

Yun Kwok Wing, PhD^h, Xiang-Dong Tang, MDⁱ, Jun-Liang Yuan, MD^c, Ping Wu, PhD^a,

^a National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China

^b School of Public Health, Peking University, Beijing, China

^c Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing 100191, China

^d Wuhan Wuchang Hospital, Wuhan University of Science and Technology, Wuhan, China

^e Beijing Friendship Hospital, Capital Medical University, Beijing, China

^f Department of Psychiatry, University of Toronto, Toronto, Canada

^g Department of Psychiatry, Baylor College of Medicine, Houston, TX, United States

h Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

¹Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Mental Health Center and Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

^j Peking-Tsinghua Centre for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China

ARTICLE INFO

Article History: Received 23 June 2021 Revised 12 August 2021 Accepted 13 August 2021 Available online xxx

Keywords: COVID-19 mental health neurological disorders susceptibility illness severity mortality

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) has evolved into a worldwide pandemic, and has been found to be closely associated with mental and neurological disorders. We aimed to comprehensively quantify the association between mental and neurological disorders, both pre-existing and subsequent, and the risk of susceptibility, severity and mortality of COVID-19.

Methods: In this systematic review and meta-analysis, we searched PubMed, Web of Science, Embase, PsycINFO, and Cochrane library databases for studies published from the inception up to January 16, 2021 and updated at July 7, 2021. Observational studies including cohort and case-control, cross-sectional studies and case series that reported risk estimates of the association between mental or neurological disorders and COVID-19 susceptibility, illness severity and mortality were included. Two researchers independently extracted data and conducted the quality assessment. Based on I² heterogeneity, we used a random effects model to calculate pooled odds ratios (OR) and 95% confidence intervals (95% CI). Subgroup analyses and meta-regression analysis were also performed. This study was registered on PROSPERO (registration number: CRD 42021230832).

Finding: A total of 149 studies (227,351,954 participants, 89,235,737 COVID-19 patients) were included in this analysis, in which 27 reported morbidity (132,727,798), 56 reported illness severity (83,097,968) and 115 reported mortality (88,878,662). Overall, mental and neurological disorders were associated with a

¹ These authors contributed equally to the manuscript.

https://doi.org/10.1016/j.eclinm.2021.101111

2589-5370/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Jie Shi, PhD^{a,***}, Yan-Ping Bao, PhD^{a,b,**}, Lin Lu, MD, PhD^{a,c,j,*}

^{*} Corresponding authors: Prof. Lin Lu, Peking University Sixth Hospital, Peking University Institute of Mental Health, National Clinical Research Centre for Mental Disorders, 51 Huayuan Bei Road, Beijing 100191, China, Tel: +86-10-82805308; Fax: +86-10-62032624

^{**} Prof. Yan-Ping Bao, National Institute on Drug Dependence, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China, Tel: +86-10-82802470; Fax: +86-10-62032624

^{***} Prof. Jie Shi, National Institute on Drug Dependence, School of Public Health, Peking University, 38 Xueyuan Road, Beijing 100191, China, Tel: +86-10-82801593; Fax: +86-10-62032624

E-mail addresses: shijie@bjmu.edu.cn (J. Shi), baoyp@bjmu.edu.cn, baoypstat@163.com (Y.-P. Bao), linlu@bjmu.edu.cn (L. Lu).

significant high risk of infection (pre-existing mental: OR 1-67, 95% Cl 1-12-2-49; and pre-existing neurological: 2-05, 1-58-2-67), illness severity (mental: pre-existing, 1-40, 1-25-1-57; sequelae, 4-85, 2-53-9-32; neurological: pre-existing, 1-43, 1-09-1-88; sequelae, 2-17, 1-45-3-24), and mortality (mental: pre-existing, 1-47, 1-26-1-72; neurological: pre-existing, 2-08, 1-61-2-69; sequelae, 2-03, 1-66-2-49) from COVID-19. Subgroup analysis revealed that association with illness severity was stronger among younger COVID-19 patients, and those with subsequent mental disorders, living in low- and middle-income regions. Younger patients with mental and neurological disorders were associated with higher mortality than elders. For type-specific mental disorders, susceptibility to contracting COVID-19 was associated with pre-existing mood disorders, anxiety, and attention-deficit hyperactivity disorder (ADHD); illness severity was associated with both preexisting and subsequent mood disorders as well as sleep disturbance; and mortality was associated with pre-existing schizophrenia. For neurological disorders, susceptibility was associated with pre-existing dementia; both severity and mortality were associated with subsequent delirium and altered mental status; besides, mortality was associated with pre-existing and subsequent description and multiple specific neurological diseases. Heterogeneities were substantial across studies in most analysis.

Interpretation: The findings show an important role of mental and neurological disorders in the context of COVID-19 and provide clues and directions for identifying and protecting vulnerable populations in the pandemic. Early detection and intervention for neurological and mental disorders are urgently needed to control morbidity and mortality induced by the COVID-19 pandemic. However, there was substantial heterogeneity among the included studies, and the results should be interpreted with caution. More studies are needed to explore long-term mental and neurological sequela, as well as the underlying brain mechanisms for the sake of elucidating the causal pathways for these associations.

Funding: This study is supported by grants from the National Key Research and Development Program of China, the National Natural Science Foundation of China, Special Research Fund of PKUHSC for Prevention and Control of COVID-19, and the Fundamental Research Funds for the Central Universities.

© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND licenses (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Panel: Research in context

Evidence before this study

We reviewed evidence of association of mental and neurological disorders with susceptibility and prognosis of COVID-19 published before July 7, 2021. PubMed, Web of Science, Embase, PsycINFO, and Cochrane library databases were searched, terms included synonyms of (1) mental disorder, neurological disorder, or a particular type of disease belong to them; (2) COVID-19; (3) susceptibility, severity or mortality. Although several previous meta-analyses reported the association of mental disorders and certain neurological diseases such as dementia and Parkinson's disease with prognosis of COVID-19, a comprehensive meta-analysis and systematic evidence on the association between mental and neurological disorders and the risk of susceptibility, severity and mortality of COVID-19 is lacking.

Added value of this study

To our knowledge, this is the first meta-analysis with a large sample size (over 227 million from 21 countries) examining the association of **pre-existing and subsequent** mental and neurological disorders with the susceptibility, illness severity, and mortality of COVID-19. Results in our study suggested that mental and neurological disorders were associated with COVID-19 infection, severity, and mortality. Subgroup analysis found the association with illness severity was significantly stronger in younger COVID-19 patients with mental sequalae, living in low- and middle-income regions, while younger cases with mental and neurological disorders were associated with mortality in a higher level.

Implications of all the available evidence

This study suggests that early detection and intervention for neurological and mental disorders are important for controlling the morbidity and mortality of the COVID-19 pandemic. More studies are needed to explore the psychiatric and neurological long-term sequela and underlying brain mechanisms and elucidate the causal pathways for these associations.

1. Introduction

Coronaviruses disease 2019 (COVID-19) has evolved into a worldwide pandemic with more than 200 million individuals infected and 4 million deaths as of August 2021, resulting in a burden of over a decade in terms of potential years of life lost [1,2]. To reduce the morbidity and mortality of the COVID-19 pandemic effectively, factors associated with high susceptibility to infection and high risks of progressing to severe illness and death in COVID-19 patients have been identified including various comorbidities [3,4]. Meanwhile, the link between mental and neurological disorders with COVID-19 have been concerned as well [5,6].

Mental and neurological disorders are common among COVID-19 patients [7]. The COVID-19 virus belongs to the genus of beta coronaviruses which also includes SARS-CoV-1 and MERS-CoV; causative agents for severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012, respectively. Beta-coronaviruses cause diseases in the central and peripheral nervous systems and commonly include mental and neurological complications [5,6,8]. The most common neurologic complaints in COVID-19 patients are anosmia, ageusia, and headache, but more serious adverse events, such as stroke, impairment of consciousness, seizure, and encephalopathy, were also reported [5]. Mental disorders among COVID-19 cases during the pandemic additionally resulted from stress and psychological problems partially due to social isolation [9-14]. A meta-analysis that included 31 studies of the psychological status of COVID-19 patients revealed that the most common psychiatric problems among patients were anxiety (47%). followed by depression (45%) and sleep disorders (34%) [15].

These mental and neurological presentations, either pre-existing or developing during coronavirus infection, were associated with illness deterioration and mortality among COVID-19 cases. A metaanalysis of 16 studies noted the likelihood of increased severity and mortality of COVID-19 with the previous history of mental illness [16]. Another recent meta-analysis suggested that the presence of pre-existing mental disorders was associated with an increased risk of COVID-19 mortality and hospitalization and the association between mortality and specific diseases such as mood disorders and substance use disorders were also observed [17]. Neurological signs after infection including delirium, confusion, agitation, and altered consciousness have already been considered to be associated with severe clinical outcomes among infections with SARS and MERS [6]. For COVID-19 patients, dementia and Parkinson's disease were also found to be predictors of increased mortality, whereas, there was no evidence for other specific neurological disorders [18,19].

It also remains controversial whether individuals with mental and neurological disorders have a higher risk of susceptibility to COVID-19 infection. A cohort from the US showed psychiatric diagnosis might be an independent risk factor for infection with COVID-19 [20]. However, another cohort from South Korea suggested a non-significant difference [21]. Similarly, as some neurological disorders such as dementia and Parkinson's disease were associated with increased susceptibility to COVID-19 [22,23], others may show insignificant results or even relation with lower incidence of COVID-19 infection in different studies [24]. The disparities in findings across studies could be explained by differences in study outcomes, demographics and clinical characteristics, as well as socioeconomic status. In addition, different types of specific neurological and psychiatric disorders may further confound the relationships, given that the biological and neurological mechanisms of the diseases may also differ.

In view of these complicated interactions of COVID-19 infection and mental and neurological disorders, a comprehensive, rigorously conducted meta-analysis is needed to assess the overall and typespecific risk of mental and neurological disorders for COVID-19 infection and clinical outcomes. We reviewed and conducted a quantitative meta-analysis on the association between mental and neurological disorders and the risk of COVID-19 incidence, illness severity and mortality for overall and type-specific disorders. We had three main objectives. (1) We calculated the pooled overall estimates of association between mental and neurological disorders and susceptibility, illness severity and death from COVID-19. (2) We evaluated the correlation between specific mental and neurological disorders and the risk of three COVID-19 outcomes. (3) We explored the sources of heterogeneity and risk factors influencing the associations. These analyses should provide evidence for preventing and managing the brain disorders morbidity and mortality associated with the COVID-19 pandemic.

2. Methods

2.1. Search Strategy and Selection Criteria

This review was conducted using parameters consistent with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [25] and GATHER (Guidelines for Accurate and Transparent Health Estimates Reporting) [26]. This study was registered on PROSPERO (registration number: CRD42021230832).

In this meta-analysis, we searched PubMed, Web of Science, Embase, PsycINFO, and Cochrane library databases for studies published from inception up to January 16, 2021 and updated at July 7, 2021. We used the following keywords to identify human studies: ("Mental Disorders" OR "Psychiatric Disease" OR "Psychiatric Disorders" OR "Anxiety" OR "Depression" OR "Insomnia" OR "Sleep disturbance" OR "Bipolar" OR "Mood Disorders" OR "Neurocognitive Disorders" OR "Dementia") AND ("COVID-19" OR "SARS-CoV-2" OR "coronavirus" OR "severe acute respiratory syndrome coronavirus 2") AND ("Susceptibility" OR "Prevalence" OR "Infection", "Incidence" OR "Critical illness" OR "Severity" OR "ICU", "mortality" OR "fatality" OR "death"). Neurological disorders such as stroke, seizures, degenerative dementias and delirium were all included as neuropsychiatric disorders, but peripheral neuropathies, inherited childhood neurological disorders and many other specific neurological syndromes and diseases were not specifically included in these searches. The search terms that were used to search the titles and abstracts are listed in the Appendix. We also scanned reference lists and review articles for additional studies that might meet the inclusion criteria.

Eight researchers (Liu L, Ni SY, Zhao YM, Xu YY, Mei H, Zeng N, Zheng YB, and Yang BN) worked in pairs to independently assess the articles for their eligibility for inclusion. They included observational studies regarding mental and neurological diseases and COVID-19 susceptibility, illness severity, and mortality, which also met the following six criteria: (1) peer-reviewed articles written in English; (2) population: general population or COVID-19 patients; (3) exposure: pre-existing and post-infection neurological and mental disorders based on standard clinical criteria or measurement tools such as the international diagnostic criteria, actual medical records, and standard questionnaires or instruments; (4) comparison: general population or COVID-19 patients without neurological and mental disorders; (5) outcomes: COVID-19 infection, illness severity, or mortality; the risk estimates of odds ratio [OR], relative risk ratio [RR], or hazard ratio [HR] should be reported or able to be calculated through provided data. The criteria for COVID-19 infection included positive laboratory results and diagnosis in conjunction with clinical presentation. Illness severity for COVID-19 was defined as hospitalization, ICU admission, or requirement for other special treatment (e.g., oxygen therapy, mechanical ventilator, extracorporeal membrane oxygenation, and cardiopulmonary resuscitation). (6) study design: cohort studies, case-control studies, case series and cross-sectional studies. We excluded reviews, case reports and studies without control groups or without available full text or data. If the same sample was used in more than one publication, only the dataset with the most comprehensive information was included to avoid data duplication in the meta-analysis.

2.2. Date Extraction

Two researchers independently conducted data extraction and quality assessment using detailed information forms. A third researcher (Bao YP) addressed any unresolved disagreement on the extracted data or its quality. The data extraction included basic study information such as first author, year of publication, country where study was conducted, survey time, study design, resources, type of participants, total sample size, mean or median age with standard deviation (SD) or interquartile range (IQR), gender distribution; other details of the analyses involving follow-up time, exposures (mental illness or neuropsychiatric disorder, and specific illness if any), temporal relationship of exposure and COVID-19 infection (pre-existing and sequelae), control group, outcomes (infection, illness severity and mortality), OR (adjusted preferred to unadjusted; if not available, replaced with number of cases in each group and each outcomes), and the statistical model used in the study.

We used the 9-star Newcastle-Ottawa Scale (NOS) to assess the study quality. We assessed the selection, comparability, and exposure in case-control studies, and similarly, the selection, comparability, and outcomes in cohort studies. Only studies with a NOS score greater than 5 were included in data synthesis.

2.3. Statistical Analysis

We calculated the pooled OR of COVID-19 susceptibility, illness severity, and mortality in different populations, each accompanied by the 95% confidence interval (95% CIs). We calculated log OR and the corresponding standard errors (SE), and then we weighted the effect size by the inverse of the standard deviation. To estimate the risk for COVID-19 incidence, the comparative groups were individuals with a diagnosis of mental or neurological disorders versus people without these diagnoses among the general or community population or from a data-linkage study. For illness severity or mortality as outcome, all participants were COVID-19 cases; COVID-19 with mental or neurological disorder versus COVID-19 cases without these problems. In studies without available OR, other risk measure (e.g., RR or HR) or exact number of each outcome in different groups were extracted and used to convert to OR. We used an I^2 statistic of $\geq 50\%$ as an indicator of large statistical heterogeneity and because of the substantial heterogeneity, we used a random effects model to calculate pooled odds ratios and 95% confidence intervals (CIs).

Subgroup analyses and meta-regression analyses were also performed to explore potential sources of heterogeneity. We conducted subgroup analyses categorized by the following variables: type of disease (mental and neurological disorder, specific disease), temporal relationship of exposure and COVID-19 infection (pre-existing vs. sequela), sex ratio (male <50% vs. male >50%) of the study sample, mean age (mean age <60 vs. mean age ≥ 60), income level of regions (high vs. low- and middle-income countries based on World Bank standard) [27], literature quality (NOS \geq 7 vs. <7) and adjustment of OR (adjusted vs. unadjusted). Evidence for differences in associations between the subgroups was quantified by the ratios of OR comparing associations in the subgroups and the corresponding P values for interaction. Studies that clearly provided essential information were included in corresponding subgroups analyses. Meta-regression for the relation between mental and neurological disorders and mean age and sex ratio (percentage male) were conducted for each outcome.

We assessed the possibility of publication bias and small-study effects of each outcome using visual examinations of funnel plots, and Egger's test. Sensitivity analyses were also conducted to identify the influence of individual studies on the pooled estimates by excluding each of the studies from the pooled estimate. All of the analyses used the statistical package Meta-Analysis in Stata 12 software.

2.4. Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results

We conducted the search on January 16, 2021 and updated on July 7, 2021. 13,475 records were included in the initial search and 9,369 remained after duplicates were removed. After excluding articles that did not meet the inclusion criteria, 286 studies (including 4 study from references) were full-text screened and finally 149 articles [20-24,28-171] were eligible and included in this analysis (Figure 1).

3.1. The characteristics of eligible studies

Among the 149 eligible articles, 227,351,954 participants were included in our meta-analysis; and 89,235,737 were COVID-19 patients. We included 27 studies (132,727,798 participants) for susceptibility [20-24,30-37,108-119,132,166], 56 studies (83,097,968 participants) for illness severity [21,24,28,31,32,34,38-41,43-62,83,108,110,116,117,120-138,167,169], and 115 studies (88,878,662 participants) for mortality [21,23,28,29,31,32,34,35,38-44,46-48,51,52,54,56,58,59,62-107,112,114-117,119,122,124,125,129-132, 139-165,167-171]. Among the 149 studies, 117 involved neurological disorders and 49 involved mental disorders. Among the 117 neurological disorders articles, 11 specific types of disorders were covered: dementia (65 studies, 43.6%), stroke (33 studies, 22.1%), Parkinson's disease (20 studies, 13.4%), delirium (15 studies), epilepsy (10 studies), altered mental status (6 studies), cognitive disorders (6 studies), and one study each for hemiplegia, neurosis, encephalopathy, and intellectual and developmental disability. 94 studies involved pre-existing neurological disorders and 36 included neurological sequelae that appeared or had been screened during hospitalization or the course of COVID-19. Among the 49 mental disorders articles, 6 types of disorders were covered: mood disorders (23 studies, 15.4%, including depression and bipolar disorder), schizophrenia (12 studies, 8.1%), anxiety (8 studies, 5.4%), sleep disturbance (7 studies), attention-deficit hyperactivity disorder (ADHD, 2 studies) and stress related disorder (2 studies). 46 studies involved pre-existing mental disorders




Figure 1. Flow chart of study selection.

13,475 records from PubMed, Web of Science, Embase, PsycINFO, and Cochrane library databases were included in the initial search and 149 articles were finally included after full-text screen.

and 5 included mental symptoms during hospitalization or the course of COVID-19, including anxiety, mood disorders and sleep disturbance. These studies covered 21 countries, including the US (39 studies), Italy (19 studies), Korea (15 studies), the United Kingdom (13 studies), China (11 studies), Iran, Brazil, Spain, Turkey, Israel, Switzerland, Netherlands, Denmark, France, Belgium, Sweden, Russian, Peru, Germany, Malaysia and Poland, and 8 studies were multinational. For the three different outcomes, most studies were retrospective. The sample size of these studies ranged from 26¹⁶² to 61,783,950³⁷, and mean age ranged from 8-8 [SD 6-7] [30] to 87 years (IQR 92-9-91-1) [69], as shown in Table 1 and supplementary.

3.2. The effect of mental and neurological disorders on susceptibility of COVID-19 infection

The meta-analysis results of 27 studies showed that overall preexisting mental (1.67, 1.12-2.49, 18 studies, n=72,464,308, I²=99.8%) and neurological disorders (2.05, 1.58-2.67, 15 studies, n=128,363,844, I²=99.7%) were associated with increased risk for COVID-19 infection. Subgroup analyses based on age, sex ratio, income region, adjusted for OR of overall mental and neurological disorder with COVID-19 susceptibility did not reveal any significant relationship (P>0.05). However, the association between neurological disorders and susceptibility was significantly stronger in studies with high literature quality than those with low literature quality (2.81, 2.07-3.10 vs. 1.18, 0.86-1.60; P=0.008; Figure 2). Meta-regression of mean age and sex ratio found that among individuals with neurological disorders, strength of the association with susceptibility increased as the male proportion increased (P=0.005). Other results from meta-regression were not significant (Figure 3).

As for specific disorders, pre-existing mood disorders (2.02, 1.08-3.76, 6 studies, l^2 =99.6%), anxiety (1.63, 1.44-1.85, 2 studies, l^2 =0), ADHD (5.82, 5.46-6.20, 1 study) and dementia (2.65, 1.45-4.85, 9 studies, l^2 =99.7%) were associated with high susceptibility to COVID-19 (Table 1).

3.3. The effect of mental and neurological disorders on illness severity of COVID-19

The meta-analysis results of 21 studies showed that mental disorders (pre-existing: 1.40, 1.25-1.57, 19 studies, I^2 =79.7%; sequelae: 4.85, 2.53-9.32, 2 studies, I^2 =14.0%) among COVID-19 cases had a significant association with illness severity. Similarly, pooled analysis of 44 studies showed that neurological disorders (pre-existing: 1.43, 1.09-1.88, 39 studies, I^2 =99.4%; sequelae: 2.17, 1.45-3.24, 5 studies, I^2 =58.1%, P>0.05) in COVID-19 patients were significantly associated with higher illness severity. Subgroup analysis found that the association with subsequent mental disorders was significantly stronger than association with pre-existing mental disorders (P=0.002). However, there was no significant difference between pre-existing neurological disorders and neurological sequelae (P>0.05).

Further subgroup analyses showed that the association between mental disorders and illness severity was higher in the middle-aged cases (mean age <60 years: 1·92, 1·48-2·51 vs. \geq 60 years: 1·20, 1·04-1·37; P=0·046) and higher in low- and middle-income regions (4·85, 2·53-9·32 vs. high-income region: 1·39, 1·24-1·55; P=0·002). Meta-regression also found that strength of association between COVID-19 severity and mental disorders reduced as the mean age of study population increased (P=0·049). The association in studies with unadjusted OR (2·73, 1·66-4·48) was stronger than those with adjusted OR (1·32, 1·19-1·46; P=0·007). Other results from subgroups analysis and meta-regressions were not significant (Figure 2, 3).

For specific diseases, both mood disorders (pre-existing, 1.34, 1.08-1.67, 8 studies, l^2 =65.9%; sequelae, 3.55, 1.41-8.93, 1 study) and sleep disturbance (pre-existing, 1.62, 1.36-1.94, 2 studies, l^2 =0; sequelae, 12.21, 3.81-39.18, 2 studies, l^2 =0) were significantly

associated with illness severity. Moreover, the association with illness severity was stronger in COVID-19 patients with subsequent sleep disturbance than those with pre-existing sleep disturbance (p=0.044). For pre-existing specific disorders, ADHD (1.93, 1.06-3.51, 1 study) and cognitive disorders (1.63, 1.54-1.73, 1 study) were associated with COVID-19 illness severity. As for sequelae, anxiety (3.23, 1.18-8.86, 1 study), altered mental status (17.28, 3.56-84.02, 2 studies, I²=68.5%) and delirium (2.29, 1.17-4.48, 2 studies, I²=85.2%) were related to illness severity (Table 1).

3.4. The effect of mental and neurological disorders on mortality of COVID-19

The meta-analysis results of 29 studies showed that pre-existing mental disorders were associated with mortality of COVID-19 patients (1.47, 1.26-1.72, 28 studies, $I^2=92.7\%$), while subsequent mental disorders were not associated with mortality (1.17, 0.97-1.43, 3 studies, $I^2=0.4\%$). For neurological disorders from 101 eligible studies, both pre-existing neurological disorders (2.08, 1.61-2.69, 74 studies, $I^2=99.3\%$) and neurological sequelae (2.03, 1.66-2.49, 34 studies, $I^2=84.2\%$) were associated with mortality, and there was no significant difference between them (p>0.05).

We further conducted subgroup analysis to explore the heterogeneity. Both mental disorders (mean age <60 years: 2.04, 0.96-4.33 vs. \geq 60 years: 1.25, 1.13-1.38; P=0.046) and neurological (mean age <60 years: 3.29, 2.07-5.25 vs. \geq 60 years: 1.78, 1.58-2.00; P=0.003) were related to mortality more strongly in middle-aged population. Meta-regression showed that the strength of association between neurological disorders and mortality decreased with age (P<0.001). (Figure 3) There was no significant difference between subgroups based on gender ratio, region based on income, adjusted for OR, literature quality for overall mental and neurological disorders (p>0.05) (Figure 2).

Analyses for specific disease showed that pre-existing disorders including mood disorders (1·36, 1·15-1·61, 14 studies, l^2 =81·4%), schizophrenia (2·28, 1·40-3·73, 8 studies, l^2 =64·0%), cognitive disorders (1·92, 1·24-2·99, 4 studies, l^2 =87·6%), Parkinson's disease (1·50, 1·06-2·10, 12 studies, l^2 =91·4%) and epilepsy (2·26, 1·84-2·78, 3 studies, l^2 =41·0%) were significantly associated with mortality. For symptoms and disorders appeared or had been screened after COVID-19 infection, subsequent altered mental status (2·09, 1·23-3·55, 6 studies, l^2 =76·7%), delirium (1·60, 1·17-2·19, 10 studies, l^2 =68·1%) and stroke (2·82, 1·74-4·57, 11 studies, l^2 =88·3%) were associated with higher mortality of COVID-19. Both pre-existing dementia (2·54, 2·11-3·05, 46 studies, l^2 =90·9%) and subsequent dementia (1·91, 1·38-2·64, 4 studies, l^2 =33·5%) were associated with mortality. (Table 1)

3.5. Publication bias and quality control

Almost all analyses except for a few subgroups showed high heterogeneity. The sensitivity analysis showed consistency on the three outcomes. Studies of severity and mortality showed publication bias (P<0.001 in Egger's test), while studies on susceptibility did not. Figure 4 shows funnel plots for these three outcomes.

4. Discussion

Our systematic review and meta-analysis provided a quantitative estimate of overall and type-specific association between mental and neurological disorders, both pre-existing and subsequent, and the risk of susceptibility to COVID-19 in the general population, as well as illness severity and mortality in COVID-19 patients. Overall, preexisting mental and neurological disorders were related to higher incidence and worse prognosis of COVID-19. Subsequent neurological disorders were associated with increased risk of illness severity and

Table 1

Subgroup analysis of odds ratios (ORs) across specific types of disorders

studies (risk gr Mental disorders Any mental disorders	,809 370,205 /) 1.67 (1.12-2.49) /	<i>I</i> ² (%) 99⋅8 /	No. of studies 19 2	Participants (risk group) 3,045,593 142	Participants (control) 22,722,005	OR (95%CI)	I ² (%)	No. of studies	Participants (risk group)	Participants (control)	OR (95%CI)	I ² (?
Any mental disorders Pre-existing 18 3,325,5 Sequelae / / ADHD - - Pre-existing 1 99,230 Sequelae / / Anxiety - - Pre-existing 2 50,809 Sequelae / / Mood disorders - - Pre-existing 6 674,99 Sequelae / / Pre-existing 10 2,526,5 Sequelae / / Non-specific mental disorders / / Pre-existing 10 2,526,5 Sequelae /	/ ,230 61,684,720 / ,809 370,205 /	/	99-8 			22 722 005							
Pre-existing 18 3,325,5 Sequelae / / ADHD Pre-existing 1 99,230 Sequelae / / ADHD Pre-existing 1 99,230 Sequelae / / Anxiety Pre-existing 2 50,809 Sequelae / / Mod disorders Pre-existing 6 674,99 Sequelae / / Sequelae Pre-existing 6 107,83 Sequelae / / Sequelae Pre-existing 1 172 Sequelae / / Sequelae Pre-existing 1 172 Sequelae Pre-existing 1 172 Sequelae Pre-existing 1 175,02 Sequelae Sequelae / / Sequelae / Pre-existing 10 2,526,5 Sequelae / Any neurological disorders Pre-existing 1 Z Sequelae / <	/ ,230 61,684,720 / ,809 370,205 /	/	99.8 			22 722 005							
Sequelae//ADHDPre-existing199,230Sequelae//AnxietyPre-existing250,809Sequelae///Pre-existing250,809SequelaePre-existing250,809Sequelae/Pre-existing6674,99Sequelae/Sequelae///Sequelae/Pre-existing6107,83Sequelae/Pre-existing1172Sequelae/Sequelae///Sequelae/Pre-existing1172Sequelae/Sequelae///Sequelae/Pre-existing1172,02Sequelae/Sequelae///Sequelae/Verse-related disordersPre-existing1172,02Sequelae///Sequelae/Veurological disorderssPre-existing11Pre-existing152,482,482,482,482,482,482,482,482,482,48	/ ,230 61,684,720 / ,809 370,205 /	/	99·8 			22 722 005							
ADHD Pre-existing 1 99,230 Jequelae / / Anxiety Pre-existing 2 50,809 Jequelae / / Mood disorders Pre-existing 6 674,99 Jequelae / / Schizophrenia Pre-existing 6 107,83 Jequelae / / Pre-existing 7 1 172 Jequelae / / Stess-related disorder Pre-existing 2 175,02 Sequelae / / Non-specific mental disorders Pre-existing 10 2,526,7 Jequelae / / Non-specific mental disorders Pre-existing 10 2,526,7 Jequelae / / Non-specific mental disorders Pre-existing 15 2,482,7 Jequelae / / Nure-existing 15 2,482,7 Jequelae / / Pre-existing 15 2,482,7 Jequelae / / Pre-existing 2 86,971 Jequelae / / Pre-existing 2 86,971 Jequelae / / Pre-existing 2 86,971 Jequelae / / Pre-existing 1 / Jequelae / / Pre-existing 2 86,971 Jequelae / / Pre-existing 9 1,139,7 Jequelae // Pre-existing 9 1,139,7 Jequelae // P	,809 370,205 /	 5·82 (5·46-6·20) 	 	2	142		1 40 (1 25-1 57) ^a	79.7	28	3,211,426	30,956,951	1 47 (1 26-1 72)	92
Pre-existing 1 99,230 Sequelae / / Anxiety 2 50,809 Pre-existing 2 50,809 Sequelae / / Mood disorders 2 50,809 Pre-existing 6 674,99 Sequelae / / Pre-existing 6 107,83 Sequelae / / Pre-existing 6 107,83 Sequelae / / Pre-existing 1 172 Sequelae / / Pre-existing 2 175,02 Sequelae / / Von-specific mental disorders / / Any neurological disorders Any neurological disorders / Any neurological disorders / / Pre-existing 15 2,482,4 Sequelae / / Pre-existing 15 2,482,4 Sequelae / / Pre-existing / /	,809 370,205 /	5·82 (5·46-6·20) /	ļ		174	93	4 85 (2 53-9 32)	14.0	3	1,290	4,478	1.17 (0.97-1.43)	0
isequelae Anxiety Pre-existing 2 50,809 jequelae Mood disorders Pre-existing 6 674,99 jequelae Schizophrenia Pre-existing 6 107,83 jequelae Scheep disturbance Pre-existing 1 172 jequelae Stress-related disorder Pre-existing 2 175,02 jequelae Stress-related disorders Pre-existing 10 2,526,] jequelae Von-specific mental disorders Pre-existing 10 2,526,] jequelae Von-specific mental disorders Pre-existing 10 2,526,] jequelae Veurological disorders Any neurological disorders Any neurological disorders Any neurological disorders Any neurological disorders Any neurological disorders Are-existing Sequelae Delirium Pre-existing 2 86,971 Sequelae Sequelae Sequelae Sequelae	,809 370,205 /	5·82 (5·46-6·20) /	1										
Anxiety 2 50,809 Pre-existing 2 50,809 Sequelae / / Pre-existing 6 674,99 Sequelae / / Schizophrenia Pre-existing 6 107,83 Sequelae / / Schizophrenia Pre-existing 6 107,83 Sequelae Pre-existing 1 172 Sequelae Pre-existing 10 2,526,7 Sequelae Pre-existing 10 2,526,7 Sequelae Any neurological disorders Pre-existing 1 Sequelae Pre-existing 1 1 Sequelae 1 Sequelae 1 1 Sequelae 1 Sequelae	I	1		1	231	1,639	1 93 (1 06-3 51)	1	/	1	/	1	1
Pre-existing 2 50,809 Sequelae / / Mood disorders Pre-existing 6 674,99 Sequelae / / Sequelae / Sequelae / / Sequelae / Se	I		/	1	/	1	/	1	1	/	/	1	1
Sequelae / / / Mood disorders Pre-existing 6 674,99 Sequelae / / Sequelae / / Pre-existing 6 107,83 Sequelae / / Pre-existing 1 172 Sequelae / / Stess-related disorder Pre-existing 2 175,02 Sequelae / / Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / Nu-specific mental disorders Pre-existing 15 2,482,7 Sequelae / / Nu-constant status Pre-existing / / Sequelae / / Pre-existing 2 86,971 Sequelae / / Pre-existing 2 86,971 Sequelae / / Pre-existing / / Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-axisting 9 1,139,4 Sequelae / / Parkinson's disease	I												
Mood disordersPre-existing6674,99Sequelae//SchizophreniaPre-existing6107,83Sequelae///Sleep disturbance//Pre-existing1172Sequelae//Stress-related disorder/Pre-existing102,526,7Sequelae//Non-specific mental disorders/Pre-existing102,526,7Sequelae//Neurological disorders/Any neurological disorders/Pre-existing152,482,7Sequelae//Pre-existing152,482,7Sequelae//Pre-existing152,482,7Sequelae//Pre-existing152,482,7Sequelae//Pre-existing//Sequelae//Pre-existing//Sequelae//Pre-existing286,971Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae/<	/ 4,997 61,635,737	1.63 (1.44-1.85)	0.0	1	1	1	1	1	4	51893	378130	1.16 (0.75-1.79)	7
Pre-existing 6 674,99 Sequelae / / Schizophrenia	4,997 61,635,737	1	1	1	67	33	3 23 (1 18-8 86)	1	1	606	2,382	1.05 (0.80-1.37)	1
Sequelae/SchizophreniaPre-existing6107,83Sequelae/Sleep disturbancePre-existing1Pre-existing1Stress-related disorderPre-existing2Pre-existing1Sequelae/Non-specific mental disordersPre-existing10Pre-existing10Sequelae//Non-specific mental disordersPre-existing10Sequelae//Neurological disordersAny neurological disordersAny neurological disordersPre-existing15Sequelae///Altered mental statusPre-existing/Pre-existing/Sequelae///Delirium/Pre-existing2Sequelae///Cognitive disorder/Pre-existing/Pre-existing/Pre-existing/Sequelae/Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9P	4,997 61,635,737												
Sequelae/SchizophreniaPre-existing6107,83Sequelae/Sleep disturbancePre-existing1Pre-existing1Stress-related disorderPre-existing2Pre-existing1Pre-existing1Sequelae/Non-specific mental disordersPre-existing10Pre-existing10Sequelae///Nurspecific mental disordersPre-existing152,482,2Sequelae///Altered mental statusPre-existing/Delirium/Pre-existing/Sequelae///Delirium/Pre-existing/Sequelae///Sequelae///Sequelae///Delirium/Pre-existing2Sequelae///Denentia/Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9Pre-existing9		2.02 (1.08-3.76)	99.6	8	3,010,065	22,605,978	1.34 (1.08-1.67)	65.9	14	3,067,474	22,991,623	1.36 (1.15-1.61)	8
Schizophrenia Pre-existing Gequelae Pre-existing Pre-exis	1	, , ,	1	1	27	73	3 55 (1 41-8 93)	1	2	1,274	3,864	1.30 (0.90-1.90)	3
Pre-existing 6 107,83 Sequelae / / / Sleep disturbance / / / Sleep disturbance / / / Sleep disturbance / / / Sre-existing 1 172 Sequelae / / / Non-specific mental disorders / / / Non-specific mental disorders Pre-existing 10 2,526, Sequelae / / / / Neurological disorders / / / Sequelae / / / / Neurological disorders / / / Pre-existing 15 2,482,2 Sequelae / / / Altered mental status Pre-existing / / Sequelae / / / Delirium Pre-existing / / Sequelae / / / Delirium Pre-existing 2 86,971 Sequelae / / / Sequelae / / / Sequelae / / / Sequelae / / / Sequelae / / / Delirium Pre-existing 2 86,971 Sequelae / / / Sequelae / / / / S	1	1	'				,	'		-,	-,		
Sequelae/Sleep disturbancePre-existing1172SequelaePre-existing2Stress-related disorderPre-existing2Sequelae/Non-specific mental disordersPre-existing102,526,iSequelae/Neurological disordersAny neurological disordersPre-existing152,482,iSequelae/Pre-existing152,482,iSequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing286,971Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-e	7,838 62,368,165	1.72 (0.62-4.77)	99.5	6	26,768	85,363	1.22 (0.70-2.13)	87.6	8	77,346	453,286	2.28 (1.40-3.73)	6
Sleep disturbance 1 172 Pre-existing 1 172 Sequelae / / Stress-related disorder Pre-existing 2 175,02 Sequelae / / / Non-specific mental disorders / / Pre-existing 10 2,526,1 Sequelae / / Nourological disorders Any neurological disorders Any neurological disorders / / Any neurological disorders / / Sequelae / / / Pre-existing 15 2,482,7 / Sequelae / / / Pre-existing / / / Sequelae / / / Pre-existing / / / Sequelae / / / Pre-existing 2 86,971 / Sequelae / / / Pre-existing / / / Sequelae	/	1 /2 (0 02 1 / /)	1	i	1	1	1 22 (0 70 2 13)	1	i	/	/	1	ĩ
Pre-existing1172Sequelae//Stress-related disorder/Pre-existing2175,02Sequelae//Non-specific mental disorders/Pre-existing102,526,7Sequelae//Neurological disorders/Any neurological disorders/Any neurological disorders/Any neurological disorders/Any neurological disorders/Any neurological disorders/Pre-existing15Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing2Sequelae/Pre-existing2Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing/Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing91,139,4Sequelae/Pre-existing/Pre-existing9Pre-existing/Pre-existing9Pre-existing/Pre-existin	1	1	/	1	1	1	1	/	1	1	1	1	1
Sequelae / / / Stress-related disorder Pre-existing 2 175,02 Sequelae / / / Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / / Neurological disorders Pre-existing 15 2,482,7 Sequelae / / / Altered mental status Pre-existing / / / Altered mental status Pre-existing / / / Delirium Pre-existing 2 86,971 Sequelae / / / Epilepsy Pre-existing 2 86,971 Sequelae / / / Cognitive disorder Pre-existing / / Sequelae / / / Dementia Pre-existing 9 1,139,4 Sequelae / / / Parkinson's disease	2 103	2.31 (0.87-5.55)	1	2	812	9.165	1 62 (1 36-1 94) ^b	0.0	2	188	534	1.47 (0.92-2.35)	0
Stress-related disorder Pre-existing 2 175,02 Sequelae / / Non-specific mental disorders / / Pre-existing 10 2,526,5 Sequelae / / Num-specific mental disorders / / Sequelae / / / Neurological disorders / / / Any neurological disorders / / / Sequelae / / / / Altered mental status Pre-existing / / / Pre-existing / / / / / Delirium / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / </td <td>2 105</td> <td>2.51 (0.07-5.55)</td> <td>1</td> <td>2</td> <td>137</td> <td>98</td> <td>12.21 (3.81-39.18)</td> <td>0.0</td> <td>1</td> <td>16</td> <td>614</td> <td>1.40(0.52-2.55) 1.40(0.53-3.68)</td> <td>1</td>	2 105	2.51 (0.07-5.55)	1	2	137	98	12.21 (3.81-39.18)	0.0	1	16	614	1.40(0.52-2.55) 1.40(0.53-3.68)	1
Pre-existing2175,02Sequelae//Non-specific mental disorders/Pre-existing102,526,iSequelae//Neurological disorders/Any neurological disorders/Pre-existing152,482,iSequelae//Pre-existing152,482,iSequelae//Pre-existing//Delirium//Pre-existing//Delirium//Pre-existing286,971Sequelae//Cognitive disorder/Pre-existing//Sequelae//Pre-existing//Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Parkinson's disease/	1	1	/	2	157	50	12.21 (3.01-39.10)	0.0	1	10	014	1.40 (0.33-3.08)	1
Sequelae / Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / Neurological disorders Any neurological disorders Any neurological disorders / / Sequelae / / Pre-existing 15 2,482,7 Sequelae / / Altered mental status / / Pre-existing / / Sequelae / / Delirium / / Pre-existing / / Sequelae / / Epilepsy / / Pre-existing 2 86,971 Sequelae / / Epilepsy / / Pre-existing 1 / Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Prea	F 0.25 414 0.21	1 05 (0 67 1 64)	50 C	1	1	1	1	1	1	50.000	270.205	2 75 (0 97 9 77)	,
Non-specific mental disorders Pre-existing 10 2,526,7 Sequelae / / Neurological disorders Any neurological disorders Any neurological disorders / Sequelae / / Pre-existing 15 2,482,7 Sequelae / / Pre-existing / / Sequelae / / Delirium / / Pre-existing / / Sequelae / / Delirium / / Pre-existing / / Sequelae / / Epilepsy / / Pre-existing 2 86,971 Sequelae / / Pre-existing 1 / Pre-existing 1 / Dementia / / Pre-existing 9 1,139,4 Sequelae / / Pre-axisting 9 1,139,4 Sequelae<	5,025 414,021	1.05 (0.67-1.64)	58·6	ļ	1	I,	1	1	1	50,809	370,205	2·75 (0·87-8·77)	
Pre-existing102,526,7Sequelae//Neurological disorders/Any neurological disordersPre-existing152,482,7Sequelae//Altered mental status/Pre-existing//Delirium//Pre-existing//Delirium//Pre-existing//Delirium//Pre-existing//Sequelae//Cognitive disorder//Pre-existing//Sequelae//Dementia//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Pre-existing91,139,4Sequelae//Parkinson's disease/	1	1	1	1	/	1	1	1	1	1	/	1	1
Sequelae / / Neurological disorders Any neurological disorders Pre-existing 15 2,482,4 Sequelae / / Altered mental status Pre-existing / / Sequelae / / Delirium Pre-existing / / Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Sequelae / / Sequelae / / Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4				_				~ -					
Neurological disorders Any neurological disorders Pre-existing Parkinson's disease	526,119 7,691,686	1 23 (1 02-1 48)	97.8	7	8,466	31,436	1 54 (1 07-2 21)	82.5	14	168,334	8,261,732	1 63 (1 05-2 53)	9
Any neurological disorders Pre-existing 15 2,482,7 Sequelae / / / Altered mental status Pre-existing / / Sequelae / / / Delirium Pre-existing / / Sequelae / / / Sequelae / / / Sequelae / / / Cognitive disorder Pre-existing / / Sequelae / / / Dementia Pre-existing 9 1,139,4 Sequelae / / / Pre-existing 9 1,139,4 Sequelae / / / Pre-existing 9 1,139,4 Sequelae / / /	1	1	/	/	/	1	/	/	1	1	/	1	1
Pre-existing 15 2,482,7 Sequelae / / Altered mental status / / Pre-existing / / Delirium / / Pre-existing / / Epilepsy / / Pre-existing 2 86,971 Sequelae / / Epilepsy / / Pre-existing 2 86,971 Sequelae / / Denetia / / Pre-existing 1 / Dementia / / Pre-existing 9 1,139,4 Sequelae / / Presensiting 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4													
Sequelae / / / Altered mental status Pre-existing / / Sequelae / / Pre-existing / / Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Sequelae / / Pre-existing / / Sequelae / / Domentia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease													
Altered mental status Pre-existing / / Sequelae / / Delirium Pre-existing / / Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Domentia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	125,881,58	2.05 (1.58-2.67)	99.7	39	2,445,582	77,691,338	1 43 (1 09-1 88)	99.4	74	2,443,487	77,898,688	2·08 (1·61-2·69)	9
Pre-existing / Sequelae / Delirium / Pre-existing / Sequelae / Pre-existing 2 Sequelae / Pre-existing 2 Sequelae / Pre-existing / Sequelae / Pre-existing 9 1,139,4 / Sequelae / Pre-existing 9 1,139,4 / Pre-existing 9 Sequelae / Pre-existing 9 Sequelae / Pre-existing 9 Sequelae / Pre-existing 9 Sequelae / Sequelae / </td <td>/</td> <td>1</td> <td>1</td> <td>5</td> <td>583</td> <td>2,753</td> <td>17 (1 45-3 24)</td> <td>58.1</td> <td>34</td> <td>5,726</td> <td>31,728</td> <td>2·03 (1·66-2·49)</td> <td>8</td>	/	1	1	5	583	2,753	17 (1 45-3 24)	58.1	34	5,726	31,728	2·03 (1·66-2·49)	8
Sequelae / / Delirium / / Pre-existing / / Epilepsy / / Fre-existing 2 86,971 Sequelae / / Cognitive disorder / / Pre-existing / / Sequelae / / / Dementia // Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-existing 9 1,139,4 Sequelae / / Pre-sisting 9 1,139,4 Sequelae / / Pre-sisting 9 1,139,4 Sequelae / /													
Delirium Pre-existing Pre-exist	1	1	1	1	/	1	/	1	1	/	/	1	1
Pre-existing / Sequelae / Epilepsy Pre-existing 2 Sequelae / Cognitive disorder Pre-existing / Sequelae / Dre-existing / Sequelae / Pre-existing / Dementia Pre-existing Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease / /	1	1	1	2	37	311	17 28 (3 56-84 02)	68.5	6	468	1,156	2.09 (1.23-3.55)	7
Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease													
Sequelae / / Epilepsy Pre-existing 2 86,971 Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	1	2	1,729	272,749	1.97 (0.89-4.38)	66.4	3	1,742	272,857	1.59 (0.56-4.51)	7
Epilepsy 2 86,971 Pre-existing 2 86,971 Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	1	2	460	1,064	2.29 (1.17-4.48)	85.2		992	4,603	1 60 (1 17-2 19)	6
Pre-existing 2 86,971 Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Domentia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	'			-,					-,		
Sequelae / / Cognitive disorder Pre-existing / / Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	.971 6.216.092	1.36 (0.41-4.51)	99.2	3	428	9.822	1.07 (0.71-1.62)	0.0	3	693	20.390	2.26 (1.84-2.78)	4
Cognitive disorder Pre-existing / Sequelae / Dementia Pre-existing 9 Sequelae / / / Parkinson's disease	/	1 50 (0 11 151)	1	i	120	/	1	1	4	76	4,058	1.52 (0.83-2.79)	3
Pre-existing / / Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	/	1	1	1	1	/	•	70	1,050	1 52 (0 05 2 75)	5
Sequelae / / Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	1	1	177,333	25,155,996	1.63 (1.54-1.73)	1	4	177,980	25,160,107	1.92 (1.24-2.99)	8
Dementia Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1		1	1	177,555	23,133,990	1.03(1.34-1.73)	1	4	119	116	1.03(0.71-1.50)	0
Pre-existing 9 1,139,4 Sequelae / / Parkinson's disease	1	1	1	1	1	1	1	1	1	119	110	1.05 (0.71-1.50)	1
Sequelae / / / Parkinson's disease	20 470 67 600 710	D CE (1 AE 4 OE)	00.7	25	10 750	240 111	1 27 (0 04 1 71)	00.4	40	15 017	207 750	0 54 (0 11 0 05)	0
Parkinson's disease	39,479 67,609,718	2.65 (1.45-4.85)	99·7	25	16,758	348,111	1.27 (0.94-1.71)	89·4	46	15,817	387,750	2·54 (2·11-3·05)	9
	1	1	1	1	1	1	1	1	4	498	1,259	1•91 (1·38-2·64)	3
re-existing 5 90,532		1.00/0.00 1.00	00.0		4 04 5 000	04400044	4 05 (0 50 0 (0)	07.0	40	4 040	0400004	4 80 /4 00 0 1	~
	,532 11,438,994	1.89 (0.88-4.09)	99·3	8	1,217,223	24,133,244	1.37 (0.78-2.42)	87.8	12	1,218,444	24,239,914	1.50 (1.06-2.10)	9
Sequelae / /	1	1	/	/	1	1	1	/	1	8	227	0.77 (0.23-2.58)	1
itroke													
Pre-existing 3 1,348,8	348.873 59.342.371	2.15 (0.83-5.55)	99.9	11	1,204,353	53,491,285	1.72 (0.82-3.61)	99.3	17	1,204,369	53,477,179	1.79 (0.82-3.90)	9
Sequelae / /	JULICIA JULICI	1	/	1	12	1,206	0.80 (0.22-2.97)	/	11	620	17,769	2 82 (1 74-4 57)	8
Non-specific neurological	 												
Pre-existing 4 19,638	 	1.38 (0.65-2.93)	98.3	6	9,309	31,523	2 00 (1 50-2 67)	52·0	10	4,224	31,677	1 47 (1 19-1 83)	4
Sequelae / /	1		1	2	111	483	2 55 (1 49-4 38)	0.0	8	3,011	8,277	2.23 (1.38-3.60)	9

Subgroup Mail Processing Processing <th></th> <th colspan="4">Susceptibility No. of Participants in Participants in</th> <th></th> <th colspan="8">Severity No. of Participants in Participants in</th> <th colspan="6">Death No. of Participants in Participants in</th>		Susceptibility No. of Participants in Participants in					Severity No. of Participants in Participants in								Death No. of Participants in Participants in					
Overall Detacts 2 500,100 127,077,073 143 (1952,000 56 4.36,077 $52,722,090$ 15 $143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 143 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 113 (1952,000 $	Subgroup				OP (9	5%(CD) I ² (%)	P value				OP (5%(CD	I2 (0/.) P value				OP (9	5%(CD) /	(%) P valu	
Discase 0-388 1 0.457,735 22.721.06 0-461 (1-22-4) 0-58 1 0.457,735 22.721.06 1 1.46 (1-30-(4-10) 0-58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.45 (1-22-4) 0.58 1.47 (1-24-17) 0.44 1.46 (1-26-6) 0.41 1.45 (1-22-4) 0.58 1.47 (1-24-17) 0.58 1.47 (1-24-17) 0.58 <th< th=""><th>Overall</th><th></th><th></th><th></th><th></th><th></th><th>1 value</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></th<>	Overall						1 value													
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		21	5,050,105	127,097,095	H	1.83 (1.30=2.30) 33.8	0.260	50	4,203,797	78,834,171		1.33 (1.24+1.92		115	4,415,661	04,402,701	H H H	1.95 (1.00=2.55)	0.010	
Neurolegical disorders is 2,482,257 125,881,587 / i 2,265 (158-2 67) 97 4 4 2,46,165 77,694,091 / i 4 2,46,165 77,694,091 i 4 4 2,446,165 77,694,091 i 4 4 2,461,165 77,694,091 i 4 4 2,446,165 77,694,091 i 4 4 2,446,165 77,694,091 i 4 4 4 1,41 (1-1,91) 993 i 3 2,446,716 7,788,728 i 4 4 4 1,41 (1-1,91) 993 i 3 2,447,71 7,788,788 i 4 4 4 1,41 (1-1,91) 993 i 3 2,447,71 7,788,788 i 4 4 4 1,41 (1-1,491) 993 i 3 4 5,152 73 i 4 4 4 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 5 200 (1,452-49) 842 i 4 4 1,41 (1-1,41,91) 993 i 4 8 (1,10-27) 982 i 4 4 4 (1,10,190 913 i 4 8 (1,10-27) 982 i 4 4 4 (1,10,190 913 i 4 8 (1,10-27) 982 i 4 4 (1,10,190 913 i 4 8 (1,10-27) 982 i 4 4 (1,10,190 913 i 1 8 (1,10-27) 98 i 4 1 4 (1,12,14,190 192 i 4 1 1 2 (1,14,131 91 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 2 i 1 4 1 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1 1 4 1		10	2 225 000	(0.120.220		1 (7 (1 12 2 10) 00 0	0.308	-	2 046 726	22 722 000		1 1/ /1 20 1 //		20	2 211 442	20.057.5/5		1 46 (1 26 1 (2)		
$ \begin{array}{c} \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$																				
$ \begin{array}{c} \text{Mend disorders} \\ \text{Sequel} \\ \text{For excissing} \\ \text{Sequel} \\ \text{Sequel} \\ \text{for } \\ \text{for } \\ \text{for } \\ \text{for } \\ \text{for excissing} \\ \text{Sequel} \\ \text{for } \\ \text{for } \\ \text{for excissing} \\ \text{Sequel} \\ \text{for } \\ \text{for excissing} \\ \text{Sequel} \\ \text{for } \\ \text{for excissing} \\ for$		15	2,482,257	125,881,587		2.05 (1.58-2.67) 99.7		44	2,446,165	77,694,091		1-48 (1-14-1-91	99.3	101	2,448,162	77,922,990		2.10 (1.69-2.60)	99-1	
$ \begin{array}{c} \text{Pre-existing} \\ \text{Sequel} \\ \text{/} \\ \text{Neurological disorders} \\ Neurologica$																			8.33	
Sequel i <							/												0.54	
Neurological disorders / $i = 2, 48, 257$ 125,88, 1587 / $i = 2, 60, 158, 2-67, 997$ 3 2,445,582 7,739 38 $i = 1, 43, (169-1, 88)$ 994 3 4 5,226 31,728 $i = 2, 20, (16-2, 69)$ 982 Regions / $i = 2, 50, 51, 582, 67, 997$ 3 5 583 2,733 $i = 1, 43, (169-1, 88)$ 994 3 4 5,228 31,728 $i = 2, 20, (16-2, 69)$ 982 Regions / $i = 2, 20, 991$ 3 70,088 $i = 2, 20, (15-2, 69)$ 997 3 2,445,582 7,739 38 $i = 1, 20, (15-2, 69)$ 993 3 1,70,08 $i = 2, 50, 51, 52, 26, 997$ 3 1,09,57 39, 241, $i = 2, 50, 51, 53, 20, 20, 156, 55, 784$ $i = 1, 41, (1-2, 1-6)$ 997 7 2 2,49,709 77,830,505 $i = 2, 20, (15-2, 26)$ 997 7 3 2,409,709 77,830,505 $i = 2, 20, (15-2, 26)$ 7 2 2,409,709 77,830,505 $i = 2, 20, (15-2, 26)$ 7 2 2,409,709 77,830,505 $i = 2, 20, (15-2, 26)$ 7 2 2,409,709 77,830,505 $i = 2, 20, (15-2, 26)$ 7 2 2,409,709 77,830,505 $i = 2, 20, (15-2, 26)$ 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 2 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 80 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 2,00 (15-2, 26) 7 9 7 7 1 1,20 (10-1,13) 7 8 8 8 9 9 9 7 7 1,20 (10-1,13) 7 8 8 8 9 9 9 7 7 1,20 (10-1,13) 7 8 8 8 9 9 9 7 7 1 2,20 (10-1,13) 7 8 8 8 9 9 9 7 7 1 2,20 (10-1,13) 7 8 8 8 9 9 9 7 7 1 2,20 (10-1,13) 7 8 9 8 1 1,10 (10-2,1) 9 9		18	3,325,988	69,138,320		1.67 (1.12-2.49) 99.8					184						H H H			
$ \begin{array}{c} \begin the transformer begin to the transformer begin to transfo$		/	/	/		/ /		2	142	93		4-85 (2-53-9-32		3	1,290	4,478		1.17 (0.97-1.43)		
Sequent / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / <th <="" th=""> / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /<!--</td--><td>Neurological disorders</td><td></td><td></td><td></td><td></td><td></td><td>/</td><td></td><td></td><td></td><td></td><td></td><td>0.376</td><td></td><td></td><td></td><td></td><td></td><td>0.88</td></th>	/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / / </td <td>Neurological disorders</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>/</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.376</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.88</td>	Neurological disorders						/						0.376						0.88
Sequet / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / </td <td>Pre-existing</td> <td>15</td> <td>2,482,257</td> <td>125,881,587</td> <td>have the second</td> <td>2.05 (1.58-2.67) 99.7</td> <td></td> <td>39</td> <td>2,445,582</td> <td>77,691,338</td> <td></td> <td>1.43 (1.09-1.88</td> <td>99.4</td> <td>74</td> <td>2,443,487</td> <td>77,898,688</td> <td></td> <td>2.08 (1.61-2.69)</td> <td>99.3</td>	Pre-existing	15	2,482,257	125,881,587	have the second	2.05 (1.58-2.67) 99.7		39	2,445,582	77,691,338		1.43 (1.09-1.88	99.4	74	2,443,487	77,898,688		2.08 (1.61-2.69)	99.3	
Regions Menal disorders I generalized biorders I generalized biorde		1	í	1		1 1		5	583			2.17 (1.45-3.24	58-1	34	5,726	31.728		2.03 (1.66-2.49)	34-2	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										-,					-,					
High-income Low-and middle-income label-and middle-income bigh-income and middle-income label-and middle-income label-							0.942						0.002						0.13	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		15	3 273 326	68 749 884		1.68 (1.10-2.57) 99.9	0 142	18	3 045 518	22 721 567	100	1-30 (1-24-1-55		27	3 160 587	30 587 284		1.41 (1.22-1.64)		
Neurological disorders 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-903 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046 0-9046											HEH									
High-forcer 14 $2,48,224$ $12,80,789$ $$ 2.06 ($1.38,2.68$) 99.7 $32,244,70$ $77,88,728$ $$ 1.44 ($1.10-1.90$) 99.3 79 $2,439,709$ $77,830,905$ $$ 2.00 ($1.58,2.54)$ 99.7 $2.20,17,828,728$ $$ 2.00 ($1.58,2.54)$ 99.7 $2.20,17,828,728$ $$ 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54)$ 99.7 2.00 ($1.58,2.54$) 99.7 2.00 ($1.58,2.54$) 99.7 2.00 ($1.58,2.54$) 99.7 2.00 ($1.58,2.54$) 99.7 1.58 ($1.10,2.70$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) 99.7 1.58 ($1.16,2.71$) <td></td> <td>- 2</td> <td>50,981</td> <td>370,308</td> <td>HHH</td> <td>1.43 (1.29-1.03) 0.0</td> <td>0.002</td> <td>2</td> <td>142</td> <td>95</td> <td></td> <td>-4.65 (2.55-9.52</td> <td></td> <td>2</td> <td>50,855</td> <td>370,201 i</td> <td></td> <td></td> <td>0.58</td>		- 2	50,981	370,308	H H H	1.43 (1.29-1.03) 0.0	0.002	2	142	95		-4.65 (2.55-9.52		2	50,855	370,201 i			0.58	
$ \begin{array}{c} Lois and middle-income 1 & 15 & 798 & \\ Metal disorders & \\ -660y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 763,044 & 1,023,023 & \\ -760y & 11 & 120,0251,089 & \\ -760y & 11 & 763,024 & \\ -760y & 242(1294-53) & 99.4 & 14 & 7,034 & 400,717 & \\ -760y & 242(1294-53) & 99.4 & 14 & 7,034 & 400,717 & \\ -760y & 11 & 123,057 & 24,408,179 & \\ -760y & 11 & 123,057 & 24,408,179 & \\ -760y & 11 & 123,057 & 24,408,179 & \\ -760y & 11 & 123,057 & 24,408,179 & \\ -760y & 11 & 129,013 & 178,912 & 60,956,052 & \\ -760y & 11 & 129,012 & 22,023,014 & \\ -760y & 11 & 129,012 & 22,012,014 & \\ -760y & 11 & 129,012 & 22,012,014 & \\ -760y & 11 & 129,012 & 22,012,014 & \\ -760y & 11 & 129,012 & 22,012,014 & \\ -760y & 110 & 199,014 & 110,019 & \\ -760y & 110 & 199,014 & 110,019 & \\ -760y & 110 & 199,014 & 110,019 & \\ -760y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 199,014 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,019 & \\ -770y & 110 & 110,019 & 110,010 & \\ -770y & 110 & 110,019 & 110,010 & \\ -770y & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,010 & \\ -770y & 110,010 & 110,010 & 110,$			2 402 242	105 000 500		2 04 (1 50 2 60) 00 7	0.903	26	0 444 770	77 (00 700		1 44 (1 10 1 00		70	2 420 200	77.030.505	1000 C	0.00 (1.60.0.60)		
Age 0-604 0-644 0-646 34,803 88,969 2-04 (0-64-33) 967 Soldy 1 763,044 1,020,023 1-18 (0-97-143) 97.5 10 34,083 60,942 1-20 (1-64-17) 887 8 3,4803 88,969 2-04 (0-66-43) 96.7 Soldy 5 152,424 6,151,452 2-242 (1-20-43) 99.8 10 123,023 40,717 1-9 (1-48-251) 81.2 8 3,4803 88,969 3-20 (2-07-525) 94.4 Neural disorders - 761 26,026 - 1-21 (1-17-27) 99.8 9.9 3,017,221 22,25,542 - 1-41 (1-24-160) 82.2 13 3,074,564 23,042,296 - 1-78 (1-39-210) 99.7 3-29 (2-075-25) 94.4 - 1-78 (1-39-210) 99.7 3-29 (2-075-25) 94.4 - 1-78 (1-39-210) 99.7 3-29 (2-075-25) 94.4 - 1-78 (1-39-210) 99.7 3-29 (2-075-25) 94.4 - 1-78 (1-39-210) 99.7 1-9 (1-1-38) 64.5 - 1-78 (1-39-210) 99.7 1-178 (1-19-16) 95.7 1-29 (1-1-31) 78.6 1-30 (1-1-38) 64.5 1-70 (1-32-16) 65.7 - 1-78 (1-39-210) 99.7 1-78 (1-39-210) 99.7 1-78 (1-39-210) 99.7 1-78 (1-39-210) 99.7 1-78 (1-39-210) 99.7 1-7																				
$ \begin{array}{c} \hline \text{Memal disorders} & & & & & & & & & & & & & & & & & & &$: 1	15	798 ⊢	-	_1·80 (0·50-6·44) /		7	456	4,449		1.88 (1.30-2.74) 78.2	16	5,263	48,516		2.06 (1.59-2.68)	18-0	
$ \begin{array}{c} c_{00y} \\ s_{00y} $																				
$\begin{array}{c} \Rightarrow 60y \\ Set 0y \\ Set 0y \\ \Rightarrow 60y \\ \Rightarrow 61 \\ Set 0y \\ Set$							0.604												0.04	
Neurological disorders $-\frac{0.831}{260}$ $-\frac{0.831}{22}$ $-\frac{0.831}{12}$ -0	<60y	11	763,044		-	1.18 (0.97-1.43) 97.5		10	34,083			1.92 (1.48-2.51	81.2	8	34,803	88,969		2.04 (0.96-4.33)	96.7	
$ \begin{array}{c} -600^{\circ} \\ -603^{\circ} \\ -60$	≥60v	3	98,032	417,480		1.31 (0.95-1.81) 93.4		8	3,010,510	22,650,579	-	1.20 (1.04-1.37	78.8	16	3,063,886	23,028,915	-	1.25 (1.13-1.38)	59.6	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Neurological disorders				-		0.536				-		0.881						0.00	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<60v	5	152.424	6.151.452		2.42 (1.29-4.53) 99.8		14	7.034	40.717		1.59 (1.16-2.17	89.7	14	9.269	79.328		3.29 (2.07-5.25)	95-4	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		4															181			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $.,						.,,					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $							0.205						0.505						0.11	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		12	2 175 012	60.056.052		1.91 (1.17 2.70) 00.8	0 205	0	2 017 221	22 625 442		1.41 (1.24 1.60		1.4	2 074 564	22 042 206	1.2.1	1.70 (1.22 2.19)		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					·															
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		4	149,927	09,458		0.95 (0.71-1.28) 90.5	0.405	11	27,815	87,950		1.12 (1.25-2.30		13	29,308	90,054	•	1.18 (1.01-1.38)		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $							0.425												0.26	
Adjust for OR Wentral disorders - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - <t< td=""><td></td><td>8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		8																		
		1	5,374	130,420	+	1.00 (0.91-1.09) /		20	3,571	43,861		1.24-2.04) 85.0	50	9,197	86,735	HEH	1.85 (1.63-2.10)	78-9	
Yes 15 $2,602,865$ $63,373,070$ $ -171(10-92-69)$ $99-9$ $173,039,863$ $22,711,184$ $ 1-32(1-19-1.46)$ 22 $2,3045,915$ $22,743,466$ $ 1-26(1-16-36)$ $60-31$ Neurological disorders 7 $1,099,780$ $61,575,76$ $ 1-12(1-18-16)$ 92.5 $2,232,2590$ $ 1-80(1-16-278)$ 92.5 $ 1-80(1-16-278)$ 92.5 $ 1-80(1-16-278)$ 92.5 $ 1-80(1-62-78)$ 92.5 $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ 2.40(164-31)$ $ -$ <																				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $							0.688												0.09	
Neurological disorders 0.091 0.091 0.091 0.055 1.29,226 24,05,757 1.84 (1 62-248) 92.8 Yes 7 1.089,780 61,555,776 - 1.51 (1:1-18-19) 92.2 1.242,341 24,479,341 - 1.89 (1:16-309) 97.8 61 1.298,926 24,005,910 - 1.84 (1:62-248) 92.8 1.89 (1:16-309) 97.8 62 1.208,956 53,318,001 - 2.40 (1:64-351) 98.7 1.89 (1:16-309) 97.8 62 1.208,956 53,318,001 - 2.40 (1:64-351) 98.7 1.89 (1:16-309) 97.8 62 1.208,956 53,318,001 - 1.84 (1:62-248) 92.8 1.00 (1:6-309) 97.8 62 1.208,956 53,318,001 - 2.40 (1:64-351) 98.7 1.89 (1:16-309) 97.8 62 1.208,956 53,318,001 - 1.86 (1:16-2:08) 95.7 1.96 (1:16-2:108) 90.91 (1:16-2:108) 92.91 (2:17 2:12,012,012,012,012,012,012,012,012,012,0	Yes	15	2,602,685					17	3,039,863		181			20	3,045,915		-	1.26 (1.16-1.36)	50-3	
Neurological disorders 0-091 0-091 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-055 0-05	No	3	723,303	5,780,813		1.42 (1.15-1.76) 95.4		4	5,872	10,914		2.73 (1.66-4.48	69.9	9	165,527	8,212,099		1.89 (1.07-3.35)	96.7	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Neurological disorders						0.091												0.11	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes	7	1.089.780	61 575 776		1.51 (1.18-1.95) 98-2		25	1 242 341	24 479 341	H H H	1.31 (1.12-1.52	93.5	63	1 239 226	24 605 744	HEH	1.84 (1.62-2.08)	2.8	
Literature Quality 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 0.291 <td></td> <td>8</td> <td>1 392 477</td> <td></td> <td></td> <td>2.77 (1.63-4.71) 99.8</td> <td></td> <td>20</td> <td></td> <td></td> <td></td> <td>1-89 (1-16-3-09</td> <td>97.8</td> <td>42</td> <td></td> <td>53 318 001</td> <td></td> <td>2.40 (1.64-3.51)</td> <td>08.7</td>		8	1 392 477			2.77 (1.63-4.71) 99.8		20				1-89 (1-16-3-09	97.8	42		53 318 001		2.40 (1.64-3.51)	08.7	
Memal disorders 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291 0-291			1,000,00	0.1,000,011		2(1.00.1.1)			1,001,100			1 05 (1 10 0 05			1,000,000					
NOS≈7 16 3,286,88 66,937,650 → 1≈0(1+6-278) 99-9 12 54,278 351,618 → 1*76(1-3+2-36) 86-5 16 107,436 765,275 → 1.56(1+0-271) 94-4 NOS~7 2,370,480 → 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 13 3,104,066 30,194,290 ↔ 1.56(1+0-13) 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,196 567 14,							0.201						0.292						0.42	
NOS<7 2 39,100 200,670 ↔ → 1-15 (0·86-1-54) 95-1 9 2,991,457 22,370,480 ↔ 1-28 (1-16-1-41) 56-7 13 3,104,006 30,194,290 ↔ 1-32 (1-17-1-50) 81-2 Neurological disorders NOS≈7 9 2,393,233 120,523,645 ↔ 2-91 (2·074-10) 99.8 16 1,216,879 53,496,113 ↔ 1-45 (0·82-2-57) 98.7 32 1,216,530 53,541,893 ↔ 2-18 (1-39-3-43) 99-3		16	2 206 000	69 027 650		1.90 (1.16 2.78) 00.0	0 291	12	64 279	261 619		1.76 (1.21 2.26		16	107 426	762 275		1.56 (1.10 2.21)		
Neurological disorders 0-031 0-831 NOS>7 9 2,393,233 120,523,645 2-14 (20,82-257) 98.7 32 1,216,530 53,541,893 2-18 (1-19)-3-43) 99-3																				
NOS≥7 9 2,393,233 120,523,645 → 2·91 (2·07-4·10) 99·8 16 1,216,879 53,496,113 → 1·45 (0·82-2·57) 98·7 32 1,216,530 53,541,893 → 2·18 (1·39-3·43) 99·3		2	39,100	200,670		1.12 (0.80-1.24) 92.1		9	2,991,457	22,370,480	H H	1.28 (1.10-1.41		13	3,104,006	30,194,290	H	1.32 (1.17-1.50)		
							0.008				1								0.60	
NOS<7 6 89,024 5,357,942 → III 8(0-86-1-60) 97-1 28 1,229,286 24,197,978 → II-46 (1-27-1-68) 91-2 69 1,231,632 24,381,097 → II-93 (1-71-2-19) 91-4					- -						•••									
	NOS<7	6	89,024	5,357,942		1.18 (0.86-1.60) 97.1		28	1,229,286	24,197,978	H	1.46 (1.27-1.68	91.2	69	1,231,632	24,381,097	H	1.93 (1.71-2.19)	91-4	
0.5 1 2 4 8 0.5 1 2 4 8 0.5 1 2 4 8				-							-	_								

Figure 2. Subgroup analysis of odds ratios (ORs) across variables.

Mental and neurological disorders were both associated with higher COVID-19 susceptibility, illness severity and mortality. Subgroup analyses suggested that the associations of mental disorders and severity varied in subgroups by temporal relationship, geographic regions, mean age and adjustments applied to OR. The association between mental and neurological disorders and mortality differed by mean age. While, there was not statistical significance observed for other subgroup analysis.

mortality among COVID-19 cases, while subsequent mental disorders were only associated with illness severity, not mortality. Subgroup analyses found that the associations with illness severity were stronger in some vulnerable subgroups including younger COVID-19 patients, those with subsequent mental disorders and living in lowand middle- income countries. We further explored the association between type-specific mental and neurological disorders and each of three outcomes. These findings urge early detection and intervention in patients with mental and neurological disorders to control the morbidity and mortality of the COVID-19 pandemic.

Individuals with pre-existing mental disorders were associated with high susceptibility to be infected, as well as increased risk of illness severity and mortality once infected. This finding is consistent with a recent meta-analysis which showed pre-existing mental disorders were associated with COVID-19-related hospitalization, intensive care unit admission and mortality [17]. Similar to previous infectious diseases including SARS and MERS, the mental stress on the population could be caused and aggravated not only by the infection but also by indirect factors such as guarantine measures, social isolation, trauma related to the disease, insufficiency of medical resources, and high economic burden [172-175]. Mental disorders may further increase the vulnerability of infection in individuals with pre-existing mental illnesses, including mood disorder, anxiety and ADHD [176]. For example, in our results, mood disorders related to a higher COVID-19 incidence (OR=2.02) and also a poorer prognosis (1.41 for severity, 1.35 for mortality) after infection. These associations may reflect the known relationship between depression and inflammatory responses [177]. Susceptibility to infection is also critical in this special population, as patients with severe mental illness are often housed in nursing homes and psychiatric hospitals, where they are more densely packed and can be insufficiently cooperative with the protections of social distancing and properly using infection control materials necessary for preventing spread of infection [178]. However, a recent Mendelian Randomization study found that positive associations between psychiatric disorders and COVID-19 may have resulted from statistical models incompletely capturing body mass index (BMI) as a continuous covariate [179]. Further studies on mechanism of mental illness and COVID-19 susceptibility are in need.

Notably, in our subgroup analyses, the association between subsequent mental disorders and illness severity was significantly higher than that of pre-existing mental disorders, especially for sleep disturbance. Mental symptoms such as sleep disturbance are common among inpatients, especially those with severe illnesses. The causes of sleep problems are complex, including high psychological stress, environmental and other factors as well as COVID-19 itself [180]. In order to improve the prognosis of COVID-19 patients, it is essential to improve their sleep quality and other mental disorders. This finding indicates that mental disorders that developed during and afterinfection should be detected and addressed early and urgently among COVID-19 cases. Other specific mental disorders except sleep disturbance appear to have similar association strength irrespective of being pre-existing or developing as a sequela. Possible reason might be the limited number of studies, as only one study for mood disorders and one for anxiety were included in this analysis. More research is needed to evaluate the risk of specific mental sequelae for the severe clinical outcome.

More attention should be paid to mortality among infected patients with schizophrenia, considering the strong association (2-28, 1.40-3.73). Schizophrenia was found to have no significant correlation with illness severity; however, these paradoxical associations may reflect selection bias and potential discrimination against those with disruptive serious mental illnesses. The schizophrenia patients appeared to have fewer chances to access advanced COVID treatments or enter ICUs, and this lack of access may be a prime contributor to their increased mortality [40]. A reduced ICU admission rate caused by discrimination against patients with schizophrenia during a time of limited allocation for medical resources would be a very serious structural problem within the world's healthcare system. COVID-19 patients with comorbid schizophrenia can over-tax the limited supply of psychiatric management that is needed along with these patients' COVID-19 treatment. A potential bias in this finding is the limited number of studies involving this special population, and specifically, one of the included studies driving this finding had a




Figure 3. Meta-regression for COVID-19 susceptibility, illness severity and death by mental and neurological disorders. Meta-regression showed that the strength of association between mental disorders and severity, and between neurological disorders and mortality decreased with age. (a). Meta-regression for mean age; (b). Meta-regression for sex ratio.

very large sample size. Clearly further studies are needed to verify this result. These findings for schizophrenia patients urgently indicate that public emergency plans in a pandemic should include consideration of structural and institutional discrimination against the seriously mentally ill patients in getting appropriate and life-saving medical care with our best technologies and medications.

COVID-19 patients with pre-existing and subsequent neurological disorders were associated with increased risk of illness severity and mortality. One basis for these two associations may be that both the SARS-CoV and SARS-CoV-2 viruses bind to the angiotensin-converting enzyme 2 (ACE2) receptors to enter human cells, and these receptors are expressed in glial cells and neurons in the brain causing changes and damage to the nervous system [181-183]. Conscious manifestations during the course of the disease, such as delirium,

altered mental status and stroke, were associated with outcomes of COVID-19 patients, as well as pre-existing neurological disorders including epilepsy and cognitive disorders. Consistent with previous meta-analyses, dementia and Parkinson's disease were also related to a higher susceptibility to COVID-19 in our study [18,19]. It's worth noting that epilepsy appears to have a protective correlation with infection. It should not be ignored, however, that patients with some neurological diseases tend to be on long-term medication and have less social interaction, and this may reduce their exposure to infection [24]. Thus, reducing mortality and improving patients' prognosis requires actively monitoring nervous system changes and taking corresponding therapeutic measures once they occur.

Subgroup analyses suggested that the association of mental disorders with COVID-19 severity was significantly higher in some




Figure 4. Funnel plot for Covid-19 susceptibility, illness severity and death.

Funnel plot and Egger's test suggested that there was publication bias among studies of COVID-19 severity and mortality, but not susceptibility. (a). susceptibility; (b). severity; (c). death

vulnerable populations, including those with young ages, and living in low- and middle-income areas. This finding is consistent with the fact that young individuals and participants living in low- and middle-income regions had higher psychological stress and burden of mental disease [184]. Low-income areas need enhanced construction of their mental health systems. The WHO's "Building Back Better" proposed that emergency situations like this pandemic could become building opportunities with external assistance and cooperation. As the male proportion increasing, the association of neurological disorders and susceptibility became stronger. Furthermore, the associations between mental disorders and illness severity, neurological disorders and mortality appear to decrease with increasing age. Thus, the male population and middle-aged COVID-19 patients with mental and neurological disorders might be target individuals for early detection during the treatment period for COVID-19 cases. Other demographics and clinical factors did not appear to be a significant source of heterogeneity.

High heterogeneity and the lack of statistical significance in some subgroups analysis indicates that results should be interpreted cautiously. Common causes of heterogeneity were differences in study design, population demographics (e.g., comorbid conditions), types of disease. Among studies on susceptibility, different sample sources (community vs. institution) and diagnosis of COVID-19 infection led to their heterogeneity; high heterogeneity among studies on severity include differences in medical systems of countries and definition of severe COVID-19 cases; and sample sources (normal patients vs. ICU patients) and limitation to death (whether included COVID-19 related death only) contributed to heterogeneity among studies on COVID-19 mortality. Further studies are needed to allow prediction of at-risk groups based on demographic data.

For clinical implementation, the association of mental and neurological disorders with the susceptibility and vulnerability of the population to COVID-19 is especially essential for individuals with some specific mental disorders including mood disorders, anxiety, sleep disturbance, schizophrenia and specific neurological disorders including dementia. They are important prognostic indicators, so rigorous detection and early intervention are important among community population during the pandemic. Facing the risk of mental and neurological disorders on susceptibility of COVID-19, the early prevention and intervention, and research priorities should be addressed. Under conditions of quarantine, social distancing and fear associated with infection, there is a need for timely monitoring and urgent public heath responses for the comprehensive management of mental and neurological disorders before potential infection [172]. Government and relevant departments should restore the routine medical services and help people face difficulties in pandemic conditions with the right attitude through health education and promotion. Actions also need to be taken to decrease the stigma associated with both mental illness and infection, while assuring regular treatment and alternative online consulting and intervention during the pandemic for vulnerable populations with certain disease like mood disorders and schizophrenia [185]. After infection, subsequent mood disorders, sleep disturbance, altered mental status and delirium were associated with severe clinical outcome, adequate supply of medical resources including experienced psychiatrists and neurologist are recommended. Identification of early signals for mental and neurological disorders in COVID-19 patients should be part of training for clinicians and other health care staff. Attention needs to be paid to specific signs during the course of the disease and targeted treatment programs should be implemented actively. In particular, the presence of psychiatric and neurological symptoms is still common in patients who have recovered from COVID-19; high burden of mental and neurological sequelae have been found in COVID-19 survivors even during recovery periods [186]. However, we did not find significant association between subsequent mental disorders and mortality among COVID-19 cases, and the possible reason is that only 3 studies were involved in this analysis. More studies of mental sequelae are needed in the future. Moreover, further research on pathological mechanisms of the neural and psychiatric disorders in COVID-19 cases, treatment protocol for patients with mental and neurological illness, and management and prevention of long-term sequelae is urgently needed (Figure 5).

This study has several limitations. First, the heterogeneity between studies is high, and publication bias was found in studies of illness severity and mortality. The extreme I^2 could also result from the small number of studies for each estimate [187]. Results in most subgroups were consistent, however, the association between mental and neurological disorders and COVID-19 should be interpreted with caution. Second, we only included studies in the English language and unpublished literatures were not included in our meta-analysis. Since we did not include all specific diseases in our search strategy, there might be omitted studies, leading to the limited generalizability in our findings. Third, the amount of research that is currently available remains inadequate, and short durations of follow up and unspecified severity of the mental and neurological disorders limited some subgroup analyses. Fourth, the number of studies on COVID-19 infection rates is relatively small, leading to a decrease in the reliability of the subgroup analyses. More specifically, few studies in low- and middle-income regions were available. Notably, a large number of participants (61 million) were from one study, which may decrease the credibility of our conclusion. Finally, as the studies were all observational and most retrospective, we cannot assign causality to the associations of neurological and mental disorders with susceptibility, illness severity or mortality of COVID-19.




Figure 5. The association of mental and neurological disorders with the risk of susceptibility and prognosis of COVID-19, and the prevention and intervention The blue arrows indicate potential associations between mental and neurological disorders and the three different outcomes, with light blue for mental disorders and dark blue for neurological disorders. The black arrows represent possible interventions for improving poor outcomes of COVID-19 susceptibility, severity and death.

To our knowledge, this is the first comprehensive meta-analysis using a large sample of more than 227 million people from 21 countries to examine the association of mental and neurological disorders, both pre-existing and subsequent, with the susceptibility, illness severity, and mortality of COVID-19. Early detection and intervention for neurological and mental disorders are urgently needed to control the morbidity and mortality of the COVID-19 pandemic. Furthermore, there was substantial heterogeneity among the included studies, and the results should be interpreted with caution. More studies are needed to explore the mental and neurological long-term sequelae and the underlying neural mechanisms, and to elucidate the causal pathways for these associations.

Declaration of Competing Interest

The authors declare that they do not have any conflicts of interest (financial or otherwise).

Funding

This study is supported by grants from the National Key Research and Development Program of China, the National Natural Science Foundation of China, Special Research Fund of PKUHSC for Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities.

Contributors

Liu L, Ni SY, and Yan W contributed equally to this article. Lu L, Bao YP and Shi J proposed the topic and main idea. Liu L and Ni SY were responsible for the literature search and study selection. Liu L, Ni SY, Zhao YM, Xu YY, Mei H, Zeng N, Zheng YB, Yang BN, and Yan W were responsible for the data extraction and quality assessment. Ni SY wrote the initial draft. Yan W, Yuan K, Sun YK, Shi L, Han Y, Deng JH, Meng SQ, Gong YM, Jiang ZD, Ravindran A, Kosten T, Wing YK, Tang XD, Yuan JL, Wu P, Shi J, Bao YP, and Lu L commented on and revised the manuscript. Lu L, Shi J, and Bao YP made the final version. All authors contributed to the final draft of the manuscript.

Data sharing

The collected study-level data and statistical analysis plan in this study are available for others after publication. Email for one of our corresponding author**s**.

Acknowledgments

This study is supported by grants from the National Key Research and Development Program of China (no. 2021YFC0863700, and 2019YFA0706200), the National Natural Science Foundation of China (no. 81761128036, 81821092 and 31900805), Special Research Fund of PKUHSC for Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities (no. BMU2020H-KYZX008).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.eclinm.2021.101111.

References

- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. August 10, 2021. https://covid19.who.int.
- [2] Hanlon P, Chadwick F, Shah A, et al. COVID-19 exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study. Wellcome Open Res 2020;5(75).
- [3] Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and metaanalysis. Diabetes Obes Metab 2020;22(10):1915–24.
- [4] Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One 2020;15(8): e0238215.
- [5] Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus aisease 2019: a review. JAMA Neurol 2020;77(8):1018–27.
- [6] Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7(7):611–27.
- [7] Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021.
- [8] Rogers JP, Watson CJ, Badenoch J, et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry 2021.
- [9] Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry 2020;25(7):1487–99.
- [10] Bao Y, Sun Y, Meng S, Shi J, Lu L. 2019-nCoV epidemic: address mental health care to empower society. Lancet 2020;395(10224):e37–e8.
- [11] Que J, Shi L, Deng J, et al. Psychological impact of the COVID-19 pandemic on healthcare workers: a cross-sectional study in China. Gen Psychiatr 2020;33(3): e100259.
- [12] Meesala N, Harsha G, Kandikatla P, Karteekvarma P, Nadakuditi S, Kakaraparthi S. Measuring the impact of COVID-19 on mental health as a preliminary procedure in primary care provision: A cross-sectional study using COVID-19 anxiety scale. J Family Med Prim Care 2020;9(11):5554–8.
- [13] Okechukwu C. The impact of loneliness on physical and mental health among older adults in the era of coronavirus disease 2019 pandemic. Apollo Medicine 2021;18(1):29–32.
- [14] Shi L, Lu ZA, Que JY, et al. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic. JAMA Netw Open 2020;3(7):e2014053.
- [15] Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci 2021;1486(1):90-111.
- [16] Toubasi AA, AbuAnzeh RB, Tawileh HBA, Aldebei RH, Alryalat SAS. A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res 2021;299:113856.
- [17] Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry 2021.
- [18] Hariyanto TI, Putri C, Situmeang RFV, Kurniawan A. Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur Arch Psychiatry Clin Neurosci 2021;271(2):393–5.
- [19] Putri C, Hariyanto TI, Hananto JE, Christian K, Situmeang RFV, Kurniawan A. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord 2021.
- [20] Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry 2020;8(2):130–40.
- [21] Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry 2020;7(12):1025–31.
- [22] Chang TS, Ding Y, Freund MK, et al. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles health system. medRxiv 2020.
- [23] Yu Y, Travaglio M, Popovic R, Leal NS, Martins LM. Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes: a UK Biobank study. Geriatrics (Basel) 2021;6(1).

- [24] Ji W, Huh K, Kang M, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci 2020;35(25):e237.
- [25] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7): e1000097.
- [26] Stevens GA, Alkema L, Black RE, et al. [Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER Statement]. Epidemiol Serv Saude 2017;26(1):215–22.
- [27] The World Bank. World Bank Country and Lending Groups. January 30, 2021. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-worldbank-country-and-lending-groups.
- [28] Ahlström B, Frithiof R, Hultström M, Larsson IM, Strandberg G, Lipcsey M. The swedish covid-19 intensive care cohort: risk factors of icu admission and icu mortality. Acta Anaesthesiol Scand 2021.
- [29] Ahmadi N, Roach J, Pynoos RS, Cardenas J, Kopelowicz A. 51.3 Clinical outcome of COVID-19 patients with and without diagnosed mental health disorder treated at the los angeles county department of health science. J Am Acad Child Adolesc Psychiatry 2020;59(10):S251–S2.
- [30] Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatrics 2020;175(2):176–84.
- [31] Caliskan T, Saylan B. Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study. Rev Assoc Med Bras (1992) 2020;66(12):1679–84.
- [32] Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy. Mov Disord 2020;35(7):1089–93.
- [33] Haderlein TP, Wong MS, Yuan A, Llorente MD, Washington DL. Association of ptsd with covid-19 testing and infection in the veterans health administration. J Psychiatr Res 2020.
- [34] Jeon HL, Kwon JS, Park SH, Shin JY. Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study. Br J Psychiatry 2021:1–8.
- [35] Matias-Guiu JA, Pytel V, Matias-Guiu J. Death rate due to COVID-19 in Alzheimer's disease and frontotemporal dementia. J Alzheimers Dis 2020;78 (2):537-41.
- [36] Najafi A, Sadeghniiat-Haghighi K, Akbarpour S, Samadi S, Rahimi B, Alemohammad ZB. The effect of apnea management on novel coronavirus infection: a study on patients with obstructive sleep apnea. Sleep Health 2020;7(1):14–8.
- [37] Wang Q. Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry 2021;20(1):124–30.
- [38] Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci 2020;75(11):2224–30.
- [39] Chachkhiani D, Soliman MY, Barua D, et al. Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization. Clin Neurol Neurosurg 2020;197:106173.
- [40] Fond G, Pauly V, Leone M, et al. Disparities inintensive care unit admission and mortality among patients with schizophrenia and COVID-19: A national cohort study. Schizophr Bull 2020.
- [41] Fond G, Pauly V, Orleans V, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. Encephale 2020;47(2):89–95.
- [42] Lee DY, Cho J, You SC, et al. Risk of mortality in elderly coronavirus disease 2019 patients with mental health disorders: a nationwide retrospective study in South Korea. Am J Geriatr Psychiatry 2020;28(12):1308–16.
- [43] Garcez FB, Aliberti MJR, Poco PCE, et al. Delirium and adverse outcomes in hospitalized patients with COVID-19. J Am Geriatr Soc 2020;68(11):2440–6.
- [44] Garcia-Azorin D, Martinez-Pias E, Trigo J, et al. Neurological comorbidity is a predictor of death in COVID-19 disease: a cohort study on 576 patients. Front Neurol 2020;11:781.
- [45] Ghaffari M, Ansari H, Beladimoghadam N, et al. Neurological features and outcome in COVID-19: dementia can predict severe disease. J Neurovirol 2021;27 (1):1–8.
- [46] Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of COVID-19 patients in the province of Reggio Emilia, Italy. PLoS One 2020;15(8):e0238281.
- [47] Ken-Dror G, Wade C, Sharma S, et al. COVID-19 outcomes in UK centre within highest health and wealth band: a prospective cohort study. BMJ Open 2020;10 (11):e042090.
- [48] Kennedy M, Helfand BKI, Gou RY, et al. Delirium in older patients with COVID-19 presenting to the emergency department. JAMA Netw Open 2020;3(11): e2029540.
- [49] Kim S-R, Nam S-H, Kim Y-R. Risk factors on the progression to clinical outcomes of COVID-19 patients in South Korea: using national data. Int J Environ Res Public Health 2020;17(23).
- [50] Maas MB, Kim M, Malkani RG, Abbott SM, Zee PC. Obstructive sleep apnea and risk of COVID-19 infection, hospitalization and respiratory failure. Sleep Breath 2020.
- [51] Miyashita S, Yamada T, Mikami T, Miyashita H, Chopra N, Rizk D. Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York. Geriatr Gerontol Int 2020;20(7):732–4.
- [52] Nalleballe K, Siddamreddy S, Sheng S, et al. Coronavirus disease 2019 in patients with prior ischemic stroke. Cureus 2020;12(9):e10231.
- [53] Qin C, Zhou L, Hu Z, et al. Clinicalcharacteristics and outcomes of COVID-19 patients with a history of stroke in Wuhan, China. Stroke 2020;51(7):2219–23.

- [54] Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol 2020;49 (5):1468–81.
- [55] Romagnolo A, Balestrino R, Imbalzano G, et al. Neurological comorbidity and severity of COVID-19. J Neurol 2020;268(3):1–8.
- [56] Samuels S, Niu J, Sareli C, Eckardt P. The epidemiology and predictors of outcomes among confirmed COVID-19 cases in a large community healthcare system in south Florida. J Community Health 2021:1–10.
- [57] Siso-Almirall A, Kostov B, Mas-Heredia M, et al. Prognostic factors in Spanish COVID-19 patients: a case series from Barcelona. Plos One 2020;15(8): e0237960.
- [58] van Gerwen M, Alsen M, Little C, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol 2021;93(2):907–15.
- [59] Vignatelli L, Zenesini C, Belotti LMB, et al. Risk of hospitalization and death for covid-19 in people with Parkinson's disease or Parkinsonism. Mov Disord 2020;36(1):1–10.
- [60] Yanover C, Mizrahi B, Kalkstein N, et al. What factors increase the risk of complications in SARS-CoV-2-infected patients? A cohort study in a nationwide israeli health organization. JMIR Public Health Surveill 2020;6(3):e20872.
- [61] Zhang J, Xu D, Xie B, et al. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study. Brain Behav Immun 2020;88:50–8.
- [62] Zhang L, Sun W, Wang Y, et al. Clinical course and mortality of stroke patients with coronavirus disease 2019 in Wuhan, China. Stroke 2020;51(9):2674–82.
- [63] Annie F, Bates MC, Nanjundappa A, Bhatt DL, Alkhouli M. Prevalence and outcomes of acute ischemic stroke among patients ≤50 years of age with laboratory confirmed COVID-19 infection. Am J Cardiol 2020;130:169–70.
- [64] Bach I, Surathi P, Montealegre N, et al. Stroke in COVID-19: a single-centre initial experience in a hotspot of the pandemic. Stroke Vasc Neurol 2020;5(4):331–6.
- [65] Battaglini D, Santori G, Chandraptham K, et al. Neurological complications and noninvasive multimodal neuromonitoring in critically ill mechanically ventilated COVID-19 patients. Front Neurol 2020;11:602114.
- [66] Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, et al. Clinical profile and predictors of in-hospital mortality among older patients admitted for COVID-19. Age Ageing 2020;50(2):326-34.
- [67] Bhargava A, Sharma M, Riederer K, Fukushima EA, Szpunar SM, Saravolatz L. Risk factors for in-hospital mortality from COVID-19 infection among black patients an urban center experience. Clin Infect Dis 2020.
- [68] Bianchetti A, Rozzini R, Guerini F, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging 2020;24(6):560–2.
- [69] Bielza R, Sanz J, Zambrana F, et al. Clinical characteristics, frailty, and mortality of residents with COVID-19 in nursing homes of a region of Madrid. J Am Med Dir Assoc 2020;22(2):245–52 e2.
- [70] Cabezudo-García P, Ciano-Petersen NL, Mena-Vázquez N, Pons-Pons G, Castro-Sánchez MV, Serrano-Castro PJ. Incidence and case fatality rate of COVID-19 in patients with active epilepsy. Neurology 2020;95(10):e1417–e25.
- [71] Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged >= 80 years. Geriatr Gerontol Int 2020;20 (7):704–8.
- [72] De Smet R, Mellaerts B, Vandewinckele H, et al. Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study. J Am Med Dir Assoc 2020;21(7):928–32 e1.
- [73] Eskandar EN, Altschul DJ, de La Garza Ramos R, et al. Neurologic syndromes predict higher in-hospital mortality in COVID-19. Neurology 2020;96(11):e1527– e38.
- [74] Esme M, Koca M, Dikmeer A, et al. Older adults with coronavirus disease 2019: a nationwide study in Turkey. J Gerontol A Biol Sci Med Sci 2020;76(3):e68–75.
- [75] Espana PP, Bilbao A, Garcia-Gutierrez S, et al. Predictors of mortality of COVID-19 in the general population and nursing homes. Intern Emerg Med 2021.
- [76] Filardo TD, Khan MR, Krawczyk N, et al. Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS One 2020;15(11):e0242760.
- [77] Frontera JA, Sabadia S, Lalchan R, et al. A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City. Neurology 2020;96(4): e575–e86.
- [78] Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med 2020;17(9):e1003321.
- [79] Hwang JM, Kim JH, Park JS, Chang MC, Park D. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci 2020;41(9):2317–24.
- [80] Jain R, Young M, Dogra S, et al. COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci 2020;414:116923.
- [81] Kim SW, Kim SM, Kim YK, et al. Clinical characteristics and outcomes of COVID-19 cohort patients in Daegu Metropolitan City outbreak in 2020. J Korean Med Sci 2021;36(1):e12.
- [82] Kummer BR, Klang E, Stein LK, Dhamoon MS, Jette N. History of stroke is independently associated with in-hospital death in patients with COVID-19. Stroke 2020;51(10):3112–4.
- [83] Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35 (23):e223.

- [84] Li J, Long X, Huang H, et al. Resilience of Alzheimer's Disease to COVID-19. J Alzheimers Dis 2020;77(1):67–73.
- [85] Li L, Li F, Fortunati F, Krystal JH. Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection. JAMA Netw Open 2020;3(9):e2023282.
- [86] Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol 2020;7(11):2221–30.
- [87] Livingston G, Rostamipour H, Gallagher P, et al. Prevalence, management, and outcomes of SARS-CoV-2 infections in older people and those with dementia in mental health wards in London, UK: a retrospective observational study. Lancet Psychiatry 2020;7(12):1054–63.
- [88] Maguire D, Woods M, Richards C, et al. Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. J Transl Med 2020;18 (1):354.
- [89] Marengoni A, Zucchelli A, Grande G, Fratiglioni L, Rizzuto D. The impact of delirium on outcomes for older adults hospitalised with COVID-19. Age Ageing 2020;49(6):923–6.
- [90] Mendes A, Herrmann FR, Genton L, et al. Incidence, characteristics and clinical relevance of acute stroke in old patients hospitalized with COVID-19. BMC Geriatr 2021;21(1):52.
- [91] Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. Clin Infect Dis 2020.
- [92] Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry 2021;78(4):380–6.
- [93] Poloni TE, Carlos AF, Cairati M, et al. Prevalence and prognostic value of delirium as the initial presentation of COVID-19 in the elderly with dementia: An Italian retrospective study. EClinicalMedicine 2020;26:100490.
- [94] Ramos-Rincon JM, Buonaiuto V, Ricci M, et al. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. J Gerontol A Biol Sci Med Sci 2020;76(3):e28–37.
- [95] Rebora P, Rozzini R, Bianchetti A, et al. Delirium in patients with SARS-CoV-2 infection: a multicenter study. J Am Geriatr Soc 2020;69(2):293–9.
- [96] Rutten JJS, van Loon AM, van Kooten J, et al. Clinical suspicion of COVID-19 in nursing home residents: symptoms and mortality risk factors. J Am Med Dir Assoc 2020;21(12):1791-7 e1.
- [97] Salahuddin H, Afreen E, Sheikh IS, et al. Neurological predictors of clinical outcomes in hospitalized patients with COVID-19. Front Neurol 2020;11:585944.
- [98] Santos MM, Lucena EES, Lima KC, Brito AAC, Bay MB, Bonfada D. Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil. Epidemiol Infect 2020;148:e198.
- [99] Sun H, Ning R, Tao Y, et al. Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: A retrospective study. J Am Geriatr Soc 2020;68(6): E19–23.
- [100] Tehrani S, Killander A, Astrand P, Jakobsson J, Gille-Johnson P. Risk factors for death in adult COVID-19 patients: Frailty predicts fatal outcome in older patients. Int J Infect Dis 2021;102:415–21.
- [101] Ticinesi A, Cerundolo N, Parise A, et al. Delirium in COVID-19: epidemiology and clinical correlations in a large group of patients admitted to an academic hospital. Aging Clin Exp Res 2020;32(10):2159–66.
- [102] Turk MA, Landes SD, Formica MK, Goss KD. Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. Disabil Health J 2020;13(3):100942.
- [103] Wan Y, Wu J, Ni L, et al. Prognosis analysis of patients with mental disorders with COVID-19: a single-center retrospective study. Aging (Albany NY) 2020;12 (12):11238–44.
- [104] Yao X, Liu S, Wang J, et al. The clinical characteristics and prognosis of COVID-19 patients with cerebral stroke: a retrospective study of 113 cases from one single-centre. Eur J Neurosci 2020;53(4):1350–61.
- [105] Zerah L, Baudouin É, Pépin M, et al. Clinical characteristics and outcomes of 821 older patients with SARS-Cov-2 infection admitted to acute care geriatric wards. J Gerontol A Biol Sci Med Sci 2020;76(3):e4–e12.
- [106] Zhai H, Lv Y, Xu Y, et al. Characteristic of parkinson's disease with severe COVID-19: a study of 10 cases from Wuhan. J Neural Transm (Vienna) 2021;128(1):1–12.
- [107] Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS. Coronavirus disease 2019 case fatality and Parkinson's disease. Mov Disord 2020;35(11):1914–5.
- [108] Bergman J, Ballin M, Nordstrom A, Nordstrom P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol 2021;36(3):287–98.
- [109] Carrat F, Touvier M, Severi G, et al. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infect Dis 2021;21(1).
- [110] Chung F, Waseem R, Pham C, et al. The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study. Sleep Breath 2021;25(2):849–60.
- [111] Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCO-VID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020;371:m3731.
- [112] De Vito A, Fiore V, Princic E, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS ONE 2021;16(3 March).
- [113] Egede C, Dawson AZ, Walker RJ, Garacci E, Campbell JA, Egede LE. Relationship between mental health diagnoses and COVID-19 test positivity, hospitalization, and mortality in Southeast Wisconsin. Psychol Med 2021:1–9.

- [114] Egede J, Campbell JA, Walker RJ, Garacci E, Dawson AZ, Egede LE. Relationship between physical and mental health comorbidities and COVID-19 positivity, hospitalization, and mortality. J Affect Disord 2021;283:94–100.
- [115] Scherbaum R, Kwon EH, Richter D, et al. Clinical profiles and mortality of COVID-19 inpatients with parkinson's disease in Germany. Mov Disord 2021;36 (5):1049–57.
- [116] Tzur Bitan D, Krieger I, Kridin K, et al. COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study. Schizophr Bull 2021.
- [117] Tahira AC, Verjovski-Almeida S, Ferreira ST. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. Alzheimers Dement 2021.
- [118] Valent F, Mazzilis G, Doimo A, Pipan C. Frequency of nasopharyngeal swab collection and positivity for SARS-CoV-2 infection in the population of the Italian province of Udine with and without chronic conditions. Health Policy 2021;125 (2):155–9.
- [119] Yang H, Chen W, Hu Y, et al. Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank cohort analysis. Lancet Healthy Longev 2020;1(2):e69– 79.
- [120] Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2021;199:143–8.
- [121] Azad MH, Khorrami F, Jahromi MK, et al. Clinical and epidemiological characteristics of hospitalized COVID-19 patients in Hormozgan, Iran: A retrospective, multicenter study. Arch Iran Med 2021;24(5):434–44.
- [122] Cummins L, Ebyarimpa I, Cheetham N, Tzortziou Brown V, Brennan K, Panovska-Griffiths J. Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data. Influenza Other Respir Viruses 2021.
- [123] Francis NA, Stuart B, Knight M, et al. Predictors of clinical deterioration in patients with suspected COVID-19 managed in a 'virtual hospital' setting: a cohort study. BMJ Open 2021;11(3).
- [124] Goldstein CA, Rizvydeen M, Conroy DA, et al. The prevalence and impact of preexisting sleep disorder diagnoses and objective sleep parameters in patients hospitalized for COVID-19. J Clin Sleep Med 2021;17(5):1039–50.
- [125] Izurieta HS, Graham DJ, Jiao Y, et al. Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among >26 million US medicare beneficiaries. J Infect Dis 2021;223(6):945–56.
- [126] McKeigue PM, Weir A, Bishop J, et al. Rapid epidemiological analysis of comorbidities and treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study. PLoS Med 2020;17(10):e1003374.
- [127] Merzon E, Weiss MD, Cortese S, et al. The association between ADHD and the severity of COVID-19 infection. J Atten Disord 2021:10870547211003659.
- [128] Mukerji SS, Das S, Alabsi H, et al. Prolonged intubation in patients with prior cerebrovascular disease and COVID-19. Front Neurol 2021;12.
- [129] Song J, Park DW, Cha JH, et al. Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study. Sci Rep 2021;11(1):10066.
- [130] Venturini S, Orso D, Cugini F, et al. Classification and analysis of outcome predictors in non-critically ill COVID-19 patients. Intern Med J 2021;51(4):506–14.
- [131] Vrotsou K, Rotaeche R, Mateo-Abad M, Machon M, Vergara I. Variables associated with COVID-19 severity: an observational study of non-paediatric confirmed cases from the general population of the Basque Country, Spain. BMJ Open 2021;11(4).
- [132] Wood A, Denholm R, Hollings S, et al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. BMJ (Clinical research ed) 2021;373:n826.
- [133] Yadav R, Yadav P, Kumar SS, Kumar R. Assessment of depression, anxiety, and sleep disturbance in COVID-19 patients at tertiary care centre of north India. J Neurosci Rural Pract 2021;12(02):316–22.
- [134] Zhou J, Lee S, Wang X, et al. Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. NPJ Digit Med 2021;4(1):66.
- [135] Brown EG, Chahine LM, Goldman SM, et al. The effect of the COVID-19 pandemic on people with Parkinson's disease. J Parkinsons Dis 2020;10(4):1365–77.
- [136] Hong KS, Lee KH, Chung JH, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J 2020;61(5):431–7.
- [137] Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic factors for severe coronavirus disease 2019 in Daegu, Korea. J Korean Med Sci 2020;35(23):e209.
- [138] Zhao J, Gao HY, Feng ZY, Wu QJ. A retrospective analysis of the clinical and epidemiological characteristics of COVID-19 patients in Henan Provincial People's Hospital, Zhengzhou, China. Front Med (Lausanne) 2020;7:286.
- [139] Amanat M, Rezaei N, Roozbeh M, et al. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurology 2021;21(1):116.
- [140] An C, Lim H, Kim DW, Chang JH, Choi YJ, Kim SW. Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep 2020;10(1):18716.
- [141] Bayrak M, Çadirci K. The associations of life quality, depression, and cognitive impairment with mortality in older adults with COVID-19: a prospective, observational study. Acta clinica Belgica 2021:1–8.
- [142] Bayrak V, Şentürk Durukan N, Demirer Aydemir F, et al. Risk factors associated with mortality in intensive care COVID-19 patients: the importance of chest CT score and intubation timing as risk factors. Turk J Med Sci 2021.

- [143] Besutti G, Ottone M, Fasano T, et al. The value of computed tomography in assessing the risk of death in COVID-19 patients presenting to the emergency room. Eur Radiol 2021.
- [144] Bhargava A, Szpunar SM, Sharma M, et al. Clinical features and risk factors for inhospital mortality from COVID-19 infection at a tertiary care medical center, at the onset of the US covid-19 pandemic. J Intensive Care Med 2021;36(6):711–8.
- [145] Brieghel C, Ellekvist P, Lund ML, et al. Prognostic factors of 90-day mortality in patients hospitalised with COVID-19. Dan Med J 2021;68(3).
- [146] Castro VM, Gunning FM, McCoy TH, Perlis RH. Mood disorders and outcomes of COVID-19 hospitalizations. Am J Psychiatry 2021;178(6):541–7.
- [147] Cho SI, Yoon S, Lee H-J. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. Sci Rep 2021;11 (1):6375.
- [148] Chou SH, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19 - a report for the GCS-Neuro-COVID Consortium and the Energy Consortium. JAMA Netw Open 2021;4(5): e2112131.
- [149] Coronado Munoz A, Tasayco J, Morales W, et al. High incidence of stroke and mortality in pediatric critical care patients with COVID-19 in Peru. Pediatr Res 2021:1–5.
- [150] Covino M, De Matteis G, Burzo ML, et al. Predicting in-hospital mortality in COVID-19 older patients with specifically developed scores. J Am Geriatr Soc 2021;69(1):37-43.
- [151] Covino M, De Matteis G, Della Polla DA, et al. Predictors of in-hospital mortality and death risk stratification among COVID-19 patients aged >80 years old. Arch Gerontol Geriatr 2021;95.
- [152] Diez-Quevedo C, Iglesias-González M, Giralt-López M, et al. Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients. Acta psychiatrica Scandinavica 2021;143(6):526–34.
- [153] Estiri H, Strasser ZH, Klann JG, Naseri P, Wagholikar KB, Murphy SN. Predicting COVID-19 mortality with electronic medical records. NPJ digital medicine 2021;4(1).
- [154] Harb AA, Chen R, Chase HS, Natarajan K, Noble JM. Clinical features and outcomes of patients with dementia compared to an aging cohort hospitalized during the initial New York City COVID-19 wave. J Alzheimers Dis 2021;81(2):679–90.
- [155] Karlsson LK, Jakobsen LH, Hollensberg L, et al. Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19-A retrospective cohort study. Arch Gerontol Geriatr 2021;94:104335.
- [156] Maniero C, Patel D, Pavithran A, et al. A retrospective cohort study of risk factors and outcomes in older patients admitted to an inner-city geriatric unit in London during first peak of COVID-19 pandemic. Ir J Med Sci 2021.
- [157] Manuel Becerra-Munoz V, Nunez-Gil IJ, Eid CM, et al. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. Age Ageing 2021;50(2):326–34.
- [158] Maripuu M, Bendix M, Ohlund L, Widerstrom M, Werneke U. Death associated with coronavirus (COVID-19) infection in individuals with severe mental disorders in Sweden during the early months of the outbreak-an exploratory cross-sectional analysis of a population-based register study. Front Psychiatry 2021;11.
- [159] Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med 2021;181(4):439–48.
- [160] Park J, Kwon Y-S, Kim H-A, et al. Clinical implications of neurological comorbidities and complications in icu patients with COVID-19. J Clin Med 2021;10(11).
- [161] Sinvani L, Marziliano A, Makhnevich A, et al. Factors associated with mortality in hospitalized older adults with covid-19: A large retrospective cohort study. J Am Geriatr Soc 2021;69(SUPPL 1):S209.
- [162] Thiam CN, Hasmukharay K, Lim WC, et al. COVID-19 infection among older people admitted to hospital: a cross-sectional analysis. Geriatrics (Basel) 2021;6(1).
- [163] Travi G, Rossotti R, Merli M, et al. Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy. Eur J Neurosci 2021;53(8):2912–22.
- [164] Tyson B, Erdodi L, Shahein A, Kamrun S, Eckles M, Agarwal P. Predictors of survival in older adults hospitalized with COVID-19. Neurol Sci 2021.
- [165] Vergara P, Rossi L, Biagi A, et al. Role of comorbidities on the mortality in patients with SARS-CoV-2 infection: an Italian cohort study. Minerva Med 2021.
- [166] Wang Q, Davis PB, Gurney ME, Xu R. COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement 2021.
- [167] Wang SM, Park SH, Kim NY, et al. Association between dementia and clinical outcome after COVID-19: a nationwide cohort study with propensity ccore matched control in South Korea. Psychiatry Investig 2021;18(6):523–9.
- [168] Wnuk M, Sawczyńska K, Kęsek T, et al. Neurological symptoms in hospitalised patients with COVID-19 and their association with in-hospital mortality. Neurol Neurochir Pol 2021.
- [169] Welch C. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study. Age Ageing 2021;50(3):617–30.
- [170] Mendes A, Serratrice C, Herrmann FR, et al. Predictors of in-hospital mortality in older patients with COVID-19: the COVIDAge Study. J Am Med Dir Assoc 2020;21(11):1546–54 e3.
- [171] Poblador-Plou B, Carmona-Pírez J, Ioakeim-Skoufa I, et al. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: results from the PRECOVID study in Spain. Int J Environ Res Public Health 2020;17(14).
- [172] Wang Y, Shi L, Que J, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry 2021:1–10.

- [173] Simon NM, Saxe GN, Marmar CR. Mental health disorders related to COVID-19related deaths. JAMA 2020;324(15):1493–4.
- [174] Nagata JM, Ganson KT, Whittle HJ, et al. Food insufficiency and mental health in the U.S. during the COVID-19 pandemic. Am J Prev Med 2021;60(4):453–61.
- [175] Yuan K, Gong YM, Liu L, et al. Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review. Mol Psychiatry 2021:1–17.
- [176] Neelam K, Duddu V, Anyim N, Neelam J, Lewis S. Pandemics and pre-existing mental illness: A systematic review and meta-analysis. Brain Behav Immun Health 2021;10:100177.
- [177] Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron 2020;107(2):234–56.
- [178] Abbasi J. "Abandoned" nursing homes continue to face critical supply and staff shortages as COVID-19 toll has mounted. JAMA 2020;324(2):123–5.
- [179] Luykx JJ, Lin BD. Are psychiatric disorders risk factors for COVID-19 susceptibility and severity? a two-sample, bidirectional, univariable, and multivariable Mendelian Randomization study. Transl Psychiatry 2021;11(1):210.
- [180] Kamdar BB, Needham DM, Collop NA. Sleep deprivation in critical illness: its role in physical and psychological recovery. J Intensive Care Med 2012;27(2):97–111.

- [181] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–74.
- [182] Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11(7):995–8.
- [183] Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-19 and SARS-CoV-2 infection: pathophysiology and clinical effects on the nervous system. World Neurosurg 2020;140:49–53.
- [184] Kola L, Kohrt BA, Hanlon C, et al. COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health. Lancet Psychiatry 2021.
- [185] Liu S, Yang L, Zhang C, et al. Online mental health services in China during the COVID-19 outbreak. Lancet Psychiatry 2020;7(4):e17–e8.
- [186] Vanderlind WM, Rabinovitz BB, Miao IY, et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment. Curr Opin Psychiatry 2021;34(4):420–33.
- [187] von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol 2015;15:35.